Curriculum Vitae

Remo Guerrini

Education:
1989: Laurea in Chimica e Tecnologia Farmaceutiche (Degree in Chemical and Pharmaceutical Technologies), University of Ferrara
1991: Laurea in Farmacia (Degree in Pharmacy), University of Ferrara
1995: PhD in Medicinal Chemistry, University of Ferrara

Professional experience:
1991-1994: PhD student, Medicinal Chemistry, University of Ferrara (Ferrara, Italy)
1996-1998: Postdoctoral Research Fellow, Medicinal Chemistry, University of Ferrara (Ferrara, Italy)
1998-2014: Assistant Professor (Ricercatore Universitario) at the Department of Pharmaceutical Sciences, University of Ferrara
2014-2018: Associate professor of Medicinal Chemistry at the Department of Pharmaceutical Sciences, University of Ferrara
November 1, 2018-present: Full professor of Medicinal Chemistry at the Department of Pharmaceutical Sciences, University of Ferrara

Nov. 2018- XX Vice director of the Department of Pharmaceutical Sciences, University of Ferrara

Research activities:
My research activities were focussed on the structure activity relationship study (SAR) of bioactive peptides, mainly neuropeptides. These activities include the SAR study of ligands for 1) the classical delta (DOP), mu (MOP) and kappa (KOP) opioid receptors 2) the nociceptin/orphanin FQ receptor (NOP); and 3) the neuropeptide S receptor (NPSR). The major achievements obtained investigating these receptor systems are summarized below.

1) SAR studies of ligands for the classical opioid receptors.

At the beginning of my academic career, SAR study of molecules able to bind DOP and MOP opiod receptors were performed. In particular the Dmt-Tic pseudodipeptide (Dmt: 2',6'-dimethyl-L-tyrosine; Tic: 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid) was identified to act as an highly potent DOP selective antagonist (Temussi et al. 1994; Salvadori et al. 1995) also when introduced in N-terminal of classical endogenous opiod ligands such as dynorphin A and enkephalin (Guerrini et al. 1998). To prevent the formation of the Dmt-Tic diketopiperazine (Capasso et al. 1995) that behaved as a low potency DOP ligand (Balboni et al 1997; Bryant et al. 1997), the Dmt-Tic pseudodipeptide was dimethylated in the N-terminal (Salvadori et al. 1997) providing the stable DOP antagonists $(CH_3)_2$-Dmt-Tic-OH. Tic features were extensively investigated (Balboni et al 2000; Santagada et al. 2000) and these studies demonstrated the important role played by this nucleus for DOP receptor binding and selectivity. The C-terminal functionalization of Dmt-Tic with hydrophobic aliphatic moieties generated potent DOP antagonist/MOP agonist ligands (Salvadori et al 1999). Interestingly, C-terminal replacement with aromatic moieties produced a series of potent opioid receptor ligands in which the distance between the Dmt-Tic pharmacophore and a third aromatic nucleus is crucial in converting Dmt-Tic from a highly potent DOP antagonist into a potent DOP agonist or into ligands with mixed DOP/MOP properties (Balboni et al. 2002a; Balboni et al. 2002b; Bryant et al. 2002; Balboni et al. 2003; Balboni et al. 2004; Balboni et al. 2005). The potent DOP agonist identified in the frame of these SAR studies, coded as UFP-512, produced robust anxiolytic- and antidepressant-like effects after intracerebroventricular and intraperitoneal administration in rodents (Vergura et al. 2008), corroborating the evidence that DOP agonists can be developed as innovative anxiolytics and antidepressants. Recently a huge panel of Dmt-Tic analogues were employed to deeply investigate the activation mechanisms of both DOP and MOP receptors (Vezzi et al.

2013). Finally, the development and pharmacological characterization of novel mixed MOP-DOP (Bird et al. 2015) and MOP-NOP (Bird et al. 2016) ligands have been performed.

2) SAR studies of ligands for the NOP receptor.

Nociceptin/orphanin FQ (N/OFQ) is a neuropeptide characterized by the following primary sequence: H-Phe-Gly-Gly-Phe-Thr-Gly-Ala-Arg-Lys-Ser-Ala-Arg-Lys-Leu-Ala-Asn-Gln-OH. N/OFQ modulates several biological functions at peripheral (respiratory, cardiovascular and renal, gastrointestinal, immune systems) and central (nociception, memory, food intake, locomotor activity, response to stress and anxiety) levels by selectively activating an opioid-like receptor named N/OFQ peptide (NOP) receptor. N/OFQ displays a primary sequence very similar to that of endogenous opioid peptides, however the presence of Phe in position 1 instead of Tyr makes this peptide highly selective for NOP over classical opioid receptors. Taking advantage from the previous knowledge accumulated with SAR studies of the classical endogenous opiod peptides, in the first SAR paper on N/OFQ (Guerrini et al. 1997) we demonstrated that (a) the entire sequence of N/OFQ may not be required for full biological activities, since N/OFQ(1-13)-NH_2 is as active as N/OFQ; (b) fragments of N/OFQ have however to be amidated as in N/OFQ(1-13)-NH_2 in order to be protected from degradation by proteases; (c) cationic residues (as Arg8,12, Lys9,13) appear to play a functional role, since their replacement with Ala in the sequence of N/OFQ(1-13)-NH_2 leads to inactivity; (d) the N-terminal tetrapeptide Phe-Gly-Gly-Phe is essential for activity: its full length and flexibility appear to be required for N/OFQ receptor activation and/or occupation; (e) Phe4 and not Phe1 appears to be the residue involved in receptor activation, since the replacement of Phe1 with Leu has no effect, while that of Phe4 leads to inactivity. Soon after, we identified the first NOP receptor antagonist (Guerrini et al 1998; Calo' et al. 1998). This peptide was generated by using N/OFQ(1-13)-NH_2 as template and reducing the Phe1-Gly2 peptide bond ([Phe1Ψ(CH_2-NH)Gly2]-N/OFQ(1-13)-NH_2). This molecule was extensively characterized in in vitro and in vivo pharmacological assays generating several collaborative papers. With the aim to increase the pharmacological properties of [Phe1Ψ(CH_2-NH)Gly2]-N/OFQ(1-13)-NH_2 the Phe1-Gly2 amide bond was replaced with a series of peptide bond isosters (Guerrini et al 2003). Unfortunately, this SAR study does not led to molecules with enhanced pharmacological properties compared to the reference peptide. On the contrary, the shift of the Phe1 benzyl side chain from C-alpha to N-terminal nitrogen generated the compound [Nphe1]N/OFQ(1-13)-NH_2 (Guerrini el al. 2000) that acted as pure NOP receptor antagonist. Also this molecule was pharmacologically investigated in a series of collaborative papers. In order to increase the potency of [Nphe1]N/OFQ(1-13)-NH_2, Nphe was replaced with a series of linear and cyclic derivatives (Guerrini et al. 2001). The SAR study of Phe4 (Guerrini et al. 2001) allowed us to demonstrate that NOP receptor agonism positively correlates with the electron withdrawal properties of the groups in the para position of Phe4 and inversely with their size. In particular, [(pF)Phe4]N/OFQ(1-13)-NH_2 was found 5-fold more potent than the reference peptide. Molecular modelling investigation and NMR analyses (Tancredi et al 2005) performed using N/OFQ analogues modified in C-terminal demonstrated that an increase of alpha helix structure together with an increase of positive charges promote an increase of biological activity. This information was employed for the design of highly potent NOP receptor ligands encompassing full and partial agonists as well as pure antagonists molecules (Guerrini et al. 2005; Arduin et al. 2007). Some interesting non peptide NOP ligands were also discovered (Trapella et al 2006; Trapella et al. 2009). Some of the molecules obtained in the frame of these SAR studies were employed in crystallization experiments. These experiments led to the structure of the NOP receptor in complex with a peptide mimetic (Thompson et al. 2012) and allow to investigate the binding mechanisms between NOP and non peptide antagonists (Miller at al. 2015). Recently, we found an innovative strategy for the synthesis of tetra branched derivatives of N/OFQ. These molecules were characterized by high potency and extraordinary long lasting effects in vivo

(Guerrini et al. 2014). Finally, the effect of ligand dimerization on NOP receptor binding and activation was investigated (Pacifico et al 2017)

3) SAR studies of ligands for the NPSR receptor.

Neuropeptide S (NPS) is the last neuropeptide identified via reverse pharmacology techniques as the endogenous ligand of the NPSR receptor. Biological functions modulated by the NPS/NPSR system include anxiety, arousal, locomotion, food intake, memory, and drug addiction. The primary sequence of NPS (in humans SFRNGVGTGMKKTSFQRAKS) is highly conserved among vertebrates especially at the N-terminus. Ala- and D-scan studies (Roth et al. 2006) demonstrated that this part of the molecule is crucial for biological activity. Focused structure–activity studies performed on Phe2 (Camarda et al. 2008), Arg3, and Asn4 (Camarda et al. 2008) confirmed this indication and revealed the chemical requirements of these positions for NPSR binding and activation. The sequence Gly5-Val6-Gly7 seems to be important for shaping the bioactive conformation of the peptide (Tancredi et al. 2007). Structure–activity studies on Gly5 allowed us to identify the first generation of peptidergic NPSR pure antagonists including [D-Cys(tBu)5]NPS, [D-Val5]NPS (Guerrini et al. 2009a), [tBu-D-Gly5]NPS and [D-Pen5]NPS (Guerrini et al. 2009b) whose antagonist properties were confirmed in vivo (Camarda et al., 2009; Ruzza et al., 2012). Medicinal chemistry as well as biological knowledge in the field of NPS have been summarized in a review article (Guerrini et al 2010). In addition, the synthesis, chromatographic separation, and pharmacological evaluation of the two enantiomers of the non peptide NPSR antagonist (9R/S)-3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide (SHA 68) was performed (Trapella et al. 2011). Recently, the chemical features required in position 5 for generating potent and pure NPS receptor antagonists were further investigated (Ruzza et al. 2014; Pela' et al. 2014). Finally, an overview of the patent literature covering NPS receptor ligands with non peptide structure has been published (Ruzza et al. 2017).

Research funds:

1996-2010: the research activities of R. Guerrini were funded with grant (**FAR**) from the University of Ferrara in the frame of projects focussed on SAR studies of bioactive peptides (PI prof. Severo Salvadori).

1997: Prin 24 months, Sintesi di peptidi bioattivi e di loro analoghi strutturali (PI R. Tomatis).

1999: Prin (9905091432_001), 24 months, pharmacology of the N/OFQ – NOP receptor system (PI prof. D. Regoli)

2001: FIRB (RBAU01CCSE_001), novel ligands for the NOP receptor (PI prof. D Regoli)

2002: Prin (2002058325_001), 24 months, pharmacology of the N/OFQ – NOP receptor system (PI prof. D. Regoli).

2003:NIH grant (RO1HL71212), 60 months, pharmacology and cardiovascular effects of N/OFQ, (PI D Kapusta, New Orleans, US).

2004: Prin (2004055475_001), 24 months, pharmacology of the N/OFQ – NOP receptor system, (PI D. Regoli).

2006: Prin 24 months, The Nociceptin/OFQ-NOP receptor: basic and clinical studies, (PI D.Regoli). During the last period of the prin 2006 project R. Guerrini acted as National Coordinator.

2006: Firb IT/USA 36 months, Nociceptin/orphanin FQ receptor ligands in the treatment of Parkinson's disease, (PI of the Italian RU R. Guerrini)

2009: Fundation Compagnia di San Paolo 36 months, Neurobiology and pharmacology of the neuropeptide S / NPSR receptor system (PI L. Raiteri).

2011:University of Ferrara research grant (FAR), 12 months, Design, synthesis and biological characterization of peptides and pseudopeptides (PI R. Guerrini).

2011: AIRC grant 36 months, Targeting ovarian cancer drug resistence, (PI M.P. Costi).
2011: Firb (RBFR109SBM_001), 36 months, studies on mixed NOP/MOP agonists, (PI C. Trapella)
2012-2017:University of Ferrara research grant (FAR), Design, synthesis and biological characterization of peptides and pseudopeptides (PI R. Guerrini).
2015: University of Ferrara research grant (PRIA), Chemical Library of UniFe (CheLiFe) generation, management and high throughput screening for the discovery of lead compounds for biomedical applications (PI R. Guerrini).
2016: Prin 36 months, NOP receptor biased agonists as innovative drugs (PI of the med. Chem. RU , R. Guerrini).
2016: In the frame of the project "**ONCOPENTA**" financed by Regione Emilia Romagna, R. Guerrini was granted with a 3-years PhD project titled "Sviluppo di chelanti per Zirconio-89 applicabili nella teranostica oncologica"

Technology transfer:
In December 2002 together with pharmacology colleagues R. Guerrini submitted a project to the Spinner organization (FSE funds) for the feasibility study of an academic spinoff. This project has been funded and in June 2003 the University of Ferrara spinoff company UFPeptides s.r.l. was constituted. UFPeptides provides products and services to pharma companies. UFPeptides activities are focused to the identification and development of molecules interacting with G-protein coupled receptors; these proteins regulate several important biological functions and are implicated in a large variety of human diseases. UFPeptides collaborated with pharma companies for the development of research projects (2004-09), performed a proprietary research project partially funded by a PRRIITT grant (FSE funds, 2006-07, project title "identificazione e caratterizzazione di nuovi farmaci ad azione antidepressiva e analgesica" total cost of the project euro 247.500; PI R. Guerrini), and made an agreement with two companies for the preclinical development of the agonopin (NOP agonists for urinary incontinence) project (2006). For this project an exclusive option license agreement has been signed by UFPeptides and Recordati in 2009 and a license agreement in 2011. The Fase I study of the agonopin project has been successfully concluded and Fase II study will start in the middle of 2017.

Patents:

1) Analogs of Nociceptin. Guerrini R, Calo' G, Salvadori S, Regoli D. Number: **EP 1422240**
2) Identificazione di un antagonista del recettore NOP a struttura 1,2,3,6-tetraidropiridinica. Trapella Claudio, Guerrini Remo, Calo' Girolamo, Regoli Domenico, Salvadori Severo. Number: **FE2004A000013**
3) Identificazione di un antagonista del recettore UT. Guerrini Remo, Salvadori Severo, Calo' Girolamo, Regoli Domenico, Lambert David. Number: **FE2004A000014**
4) Agonisti pieni e parziali ed antagonisti del recettore per nocicettiva/orfanina FQ ad elevata potenza. Guerrini Remo, Calo' Girolamo, Regoli Domenico, Salvadori Severo. Number: **FE2005A000003**
5) Preparation of analogues of the Dmt-Tic pharmacophore for identifying δ and μ opioid receptors. Lazarus Lawrence H, Salvadori Severo, Balboni Gianfranco, Guerrini Remo. Number: **US 2005-280752**
6) Identificazione di un agonista parziale del recettore per il neuropeptide S. Guerrini Remo, Calo' Girolamo, Regoli Domenico, Salvadori Severo. Number: **FE2006A000003**
7) Antagonisti del recettore UT e loro usi terapeutici. Gavioli Elaine Cristina, Guerrini Remo, Calo' Girolamo, Regoli Domenico, Salvadori Severo. Number: **FE2006A000007**

8) Highly potent full and partial agonists and antagonists of the nociceptin/orphanin FQ receptor. Guerrini Remo, Calo' Girolamo, Regoli Domenico, Salvadori Severo. Number: **PCT/EP2006/050958**
9) Biologically potent analogues of the Dmt-Tic pharmacophore and methods of use. Lazarus Lawrence H.; Salvadori Severo; Balboni Gianfranco; Guerrini Remo. Number: **US 2006-0104907**
10) Analoghi dermaseptinici ad attivita' antimicrobica. Guerrini Remo, Calo' Girolamo, Regoli Domenico, Salvadori Severo, Erika Marzola, Dianella Savoia. Number: **FE2006A000014**
11) Identificazione di antagonisti puri di elevata potenza del recettore per il neuropeptide S. Guerrini Remo, Calo' Girolamo, Regoli Domenico, Rainer K Reinscheid, Salvadori Severo. Number: **FE2008A000028.**
12) Composizioni cosmetiche contenenti composti con azione anti-glicazione da usare per prevenire e rallentare il processo di invecchiamento cutaneo. Apone Fabio, Colucci Maria G., Cucchiara Jerez Mirna, De Laurentiis Francesco, Guerrini Remo, Massarotti Sergio. Number: **ITMI20102250**
13) Supramolecular aggregates comprising maleimido cores. Guerrini Remo, Salvadori Severo. Girolamo Calo'. **European Patent Application n° 13162532.9**, filled: April 5, 2013
This Patent describes the synthesis of tetra branched peptides characterized by high purity, high yield and reproducibility. The molecules contained in this patent act as GPCR ligands with long lasting activity in vivo.

Teaching activities:

1992-1999, R. Guerrini acted as collaborator of prof. Severo Salvadori for the practical laboratory activities for the course of Analyses of Drugs III, Degree in Chemical and Pharmaceutical Technologies
2000-present, responsible of the course of Qualitative Analyses of Drugs, Degree in Chemical and Pharmaceutical Technologies, University of Ferrara.
2010-present R. Guerrini is a member of the Graduate School Committee (PhD school) in Medicinal Chemistry of the University of Ferrara
2010-present postgraduate course (level 2) in Cosmetic Science and Technology (COSMAST) University of Ferrara
November 2009 to February 2010, tutor of Dr. Dalal Naima with a Fellowship granted by International Atomic Energy Agency (IAEA)
April-July 2011 , tutor of Dr. Katarina Smilkov with a Fellowship granted by International Atomic Energy Agency (IAEA)
2013-2016 postgraduate course (level 1) in "Aspects of Regulation, Patenting and Economics in Drug Development", University of Ferrara
2015-present Coordinator of the degree course in Chemical and Pharmaceutical Technologies, University of Ferrara
2016-2017 Tutor for a research fellowship titled "Design and synthesis of homo – and hetero-tetrameriche molecules", University of Ferrara
2016-present, R. Guerrini acted as tutor of the PhD student Valentina Albanese funded in a frame of a PhD program of Regione Emilia Romagna.

R. Guerrini is member of the following examiner commission:
Medicinal chemistry II for the Degree in Chemical and Pharmaceutical Technologies
Medicinal chemistry II for the Degree in Pharmacy.
From 1998 to present R. Guerrini acted as tutor of about 30 experimental thesis and 1 PhD thesis.

Professional Membership and consultancies:

1998-present: Remo Guerrini is a member of the Italian Society of Chemistry.
2007 Member of the examination committee for the qualification to the profession of pharmacist
2009-present: R. Guerrini is a member of the Editorial board of International Journal of Peptides (https://www.hindawi.com/journals/ijpep/editors/).
R. Guerrini acts as referee for the following scientific journals: Journal of Medicinal Chemistry, European Journal of Medicinal Chemistry, Bioorganic & Medicinal Chemistry, Bioorganic & Medicinal Chemistry Letters, Peptides
2010-present: Remo Guerrini is a member "Socio Ordinario" classe di scienze matematiche, fisiche, chimiche naturali" of the Accademia delle Scienze di Ferrara. http://www.accademiascienze.ferrara.it/
2010-present: Remo Guerrini is the technical director of the section Molecular Interactions Biomarkers and Delivery of the Laboratorio per le Tecnologie delle Terapie Avanzate (LTTA) of the Tecnopolo, Universita' di Ferrara.
http://ltta.tecnopoloferrara.it/contact.php?G=eNortjKyUjJ1VrIGXDALZAIR
Remo Guerrini performed consulting work for the following companies: Recordati S.p.A. (Pharmaceutical Company) and Intercos S.p.A. (Cosmetic Company, Agrate Brianza, Italy)

Invited lectures and organizing committee:

November, 16 2001 Zealand Pharmaceuticals, Copenhagen Denmark
Medicinal chemistry of OP4 receptor: agonists and antagonists
June 18, 2003 Italfarmaco s.p.a. Milano
Ligands for the NOP receptor
November 12, 2003 Gruppo Angelini, Pomezia, ROMA
Novel peptide ligands for the NOP receptor: full e partial agonists and pure antagonists
30 maggio 2 giugno 2001. XXX Congresso Nazionale della Società Italiana di Farmacologia. Genova. Agonisti ed antagonisti per il recettore OP4
18-22 settembre 2002. XVI Convegno Nazionale della Divisione di Chimica Farmaceutica. Sorrento. Struttura-Attività del neuropeptide Nocicettina/Orfanina FQ
8-11 April 2008, member of the Organizing Committee of the European Opioid Conference / European Neuropeptide Club joint meeting, , Ferrara, Italy
http://www.unife.it/dipartimento/medicina/eventi/European%20Opioid%20Conference.pdf
22-26 November 2010 Vienna, invited speaker at the 3nd Research Co-ordination Meeting of the CRP on 'Development of ^{99m}Tc Radiopharmaceuticals for Sentinel Node Detection and Cancer Diagnosis' organized by International Atomic Energy Agency (IAEA)
12-16 Settembre 2010. XX National Meeting on Medicinal Chemistry, della Società Chimica Italiana. Abano Terme (Pd), Italia "UFPeptides s.r.l. a spinoff company of the University of Ferrara"

List of Publications:

Remo Guerrini is included in the list of Top UniFE Scientists of the Scopus Highly Cited Italian Scientists: http://www.via-academy.org/VIA/index.php?title=Scopus_Highly_Cited_Italian_Scientists#Ranking_of_SCOPUS_citation_rate_for_large_Italian_Institutes

ORCID iD: 0000-0002-7619-0918

Bibliometric parameters:

1) **Total citations: 8805 (SCOPUS)**

2) **Average citation of publications: 30.5 (SCOPUS)**

3) **Total IF: 1078.203 (Journal Citation Reports 2015)**

4) **Average IF of publications; 3.77**

5) **H-index (SCOPUS): 48**

Book chapters:

1) Calo G, and Guerrini R. (2013) Medicinal chemistry, pharmacology, and biological actions of peptide ligands selective for the nociceptin/orphanin FQ receptor. In Ko MC and Husbands SM (eds.) Research and development of opioid-related ligands. ACS symposium series 2013;1131:275-325, ISBN: 978-0-8412-2782-8Oxford University Press.

2) Calo', G., Lambert, D.G. & Guerrini, R. (2013) Nociceptin/orphanin FQ (Chapter 215). In: Handbook of biologically active peptides, ISBN: 978-0-12-385095-9 (Kastin, A. J., ed): Elsevier.

Papers:

1) Synthesis and pharmacological activity of the N-terminal
Dermorphin tetrapeptide analogues with CH_2-NH peptide bond isosteres.
S.Salvadori, *R.Guerrini*, P.A.Borea, R.Tomatis
Int. J. Peptide Protein Res. 40, 1992, 437-444

2) Prerequisite for His^4 in Deltorphin A for High δ Opioid Receptor Selectivity
S.Salvadori,, *R.Guerrini*, V.Forlani, S.D.Bryant, L.H.Lazarus
Amino Acids 7, 1994, 291-304

3) Selective Opioid Dipeptides
P.A.Temussi, S.Salvadori, P.Amodeo, C.Bianchi, *R.Guerrini*, R.Tomatis, L.H.Lazarus, D.Picone and T.Tancredi
Biochem. Biophys. Res. Com. 198 ,1994, 933-939

4) Molecular Dynamics Conformation of Deltorphin Analogues Advocate δ Opioid Binding Site Models
S. D. Bryant, M. Attila, S. Salvadori *R. Guerrini*, L.H. Lazarus
Peptide Research 7, 1994, 175-184

5) Conversion of Enkephalin and Dermorphin Into δ-Selective Opioid Antagonist by Single-Residue Substitution

T. Tancredi, S. Salvadori, P. Amodeo, D. Picone, L.H. Lazarus, S.D. Bryant, *R. Guerrini*, G. Marzola, P.A. Temussi
Eur. J. Biochem. 224, 1994, 241-247

6) Identification and Characterization of Three Calmodulin Binding Sites of the Skeletal Muscle Ryanodine Receptor
P. Menegazzi, F. Larini, S. Treves, *R. Guerrini*, M. Quadroni, F. Zorzato
Biochemistry 33, 1994, 9078-9084

7) Conformationally Constrained Amino Acids: a Concise Route to a Methionine Analogue
G. Fantin, M. Fogagnolo, *R. Guerrini*, M. Marastoni, A. Medici, P. Pedrini
Tetrahedron 50, 1994, 12973-12978

8)Effect of anchor residue modification on the stability of HLA-A11/Peptide complexes.
R.Gavioli, Q.J.Zhang, M.Marastoni, *R.Guerrini*, E.Reali, R.Tomatis, M.G.Masucci, S.Traniello
Biochem. Biophys. Res. Com.. 206, 1995, 8-14

9)Synthetic peptides presented by the mutant T2 cell line induce virus specific cytotoxic T lymphocytes
E.Reali, B.Giori, M.Marastoni, *R.Guerrini*, S.Spisani, R.Tomatis, S.Traniello, R.Gavioli.
J. Exp. Clin. Cancer Research 14, 1995, 108-109

10)Acid catalysis in the formation of dioxopiperazines from peptides containing tetrahydroisoquinoline-3-carboxylic acid at position 2
S.Capasso, F.Sica, L.Mazzarella, G.Balboni, *R.Guerrini*, S.Salvadori.
Int. J. Peptide Protein Res. 45, 1995, 567-573

11)Calmodulin binding sites of the skeletal, cardiac and brain ryanodine receptor Ca^{2+} channels: modulation by the catalytic subunit of cAMP dependent protein kinase?
R.Guerrini, P.Menegazzi, R.Anacardio, M.Marastoni, R.Tomatis, F.Zorzato, S.Treves.
Biochemistry 34, 1995, 5120-5129

12) δ opioidmimetic antagonists: prototypes for designing a new generation of ultraselective opioid peptides.
S.Salvadori, M.Attila, G.Balboni, C.Bianchi, S.D.Bryant, O.Crescenzi, *R.Guerrini*, D.Picone, T.Tancredi, P.A.Temussi, L.H.Lazarus.
Molecular Medicine 1, 1995, 678-689

13) Binary and ternary CU^{II} complexes of L-spinacine in aqueous solution.
M.Remelli, S.Rossi, *R.Guerrini*, F.Pulidori.
Annali di Chimica 85, 1995, 503-518

14) Conformational analysis of potent and very selective δ opioid dipeptide antagonists
P.Amodeo, G.Balboni, O.Crescenzi, *R.Guerrini*, D.Picone, S.Salvadori, T.Tancredi, P.A.Temussi.
FEBS Letters 377, 1995, 363-367

15) Opioid receptor selectivity alteration by single residue replacement. Synthesis and activity profile of [Dmt^1] Deltorphin B.

R.Guerrini, A.Capasso, L.Sorrentino, R.Anacardio, S.D.Bryant, L.H.Lazarus, M.Attilsa, S.Salvadori.
Eur. J. Pharm. 302, 1996, 37-42

16) Design and synthesis of 1-Aminocycloalkane-1-carboxylic acid-substituted deltorphin analogues: unique δ and μ opioid activity in modified peptides.
A.Breveglieri, *R.Guerrini*, S.Salvadori, C.Bianchi, S.D.Bryant, M.Attila, L.H.Lazarus.
J. Med. Chem. 39, 1996, 773-779

17) Activation of epitope-specific memory cytotoxic T lymphocyte responses by synthetic peptides
E.Reali, *R.Guerrini*, B.Giori, M.Borghi, M.Marastoni, R.Tomatis, S.Traniello, M.G.Masucci, R.Gavioli
Clin. Exp. Immunol. 105, 1996, 369-375

18) The mouse vas deferens: a pharmacological preparation sensitive to nociceptin
G.Calò, A.Rizzi, G.Bogoni, V.Neugebauer, S.Salvadori, *R.Guerrini*, C.Bianchi, D.Regoli
Eur. J. Pharm. 311, 1996, R3-R5

19) Polymorphonuclear neutrophils pulsed with synthetic peptides efficiently activate memory cytotoxic T lymphocytes
E.Reali, *R.Guerrini*, S.Moretti, S.Spisani, F.Lanza, R.Tomatis, S.Traniello, R.Gavioli
J. Leuk. Biol. 60, 1996, 207-213.

20) Dmt-Tic-OH, a highly selective and potent δ-opioid dipeptide receptor antagonist after systemic administration in the mouse
A.Capasso, *R.Guerrini*, G.Balboni, L.Sorrentino, P.Temussi, L.H.Lazarus, S.D.Bryant, S.Salvadori
Life Sciences 59, 1996, PL 93-98

21) δ-Selective opioid peptides containing a single aromatic residue in the message domain: an NMR conformational analysis
O.Crescenzi, P.Amodeo, G.Cavicchioni, *R.Guerrini*, D.Picone, S.Salvadori, T.Tancredi, P.A.Temussi
Journal of Peptide Science 2, 1996, 290-308

22) Opioid Diketopiperazines: Synthesis and activity of a prototypic class of opioid antagonists
G.Balboni, *R.Guerrini*, S.Salvadori, R.Tomatis, S.D.Bryant, C.Bianchi, M.Attila, L.H.Lazarus
Biol. Chem. 378, 1997, 19-29

23) Opioid Diketopiperazines: Refiniment of the δ Opioid Antagonist Pharmacophore
S.D.Bryant, G.Balboni, *R.Guerrini*, S.Salvadori, R.Tomatis, L.H.Lazarus
Biol. Chem. 378, 1997, 107-114

24) Address and message sequences for the nociceptin receptor: A structure-activity study of nociceptin (1-13) amide
R.Guerrini, G.Calò, A.Rizzi, C.Bianchi, L.H.Lazarus, S.Salvadori, P.A.Temussi, D.Regoli
J. Med. Chem. 40, 1997, 1789-1793

25) Solution conformation of Nociceptin

S.Salvadori, D.Picone, T.Tancredi, *R.Guerrini*, R.Spadaccini, L.H.Lazarus, D.Regoli, P.A.Temussi
Biochem. Biophys. Res. Com. 233, 1997, 640-643

26) Pharmacological characterization of nociceptin receptor: an in vitro study
G.Calò, A.Rizzi, M.Bodin, W.Neugebauer, S.Salvadori, *R.Guerrini*, C.Bianchi, D.Regoli
Can. J. Physiol. Pharmacol. 75, 1997, 713-718

27) Synthesis and pharmacological activity of deltorphin and dermorphin related glycopeptides
R.Tomatis, M.Marastoni, G.Balboni, *R.Guerrini*, A.Capasso, L.Sorrentino, V.Santagada, G.Caliendo, L.H.Lazarus S.Salvadori
J. Med. Chem. 40, 1997, 2948-2952

28) Helix-inducing α-aminoisobutyric acid in opioidmimetic deltorphin C analogues
S.D.Bryant, *R.Guerrini*, S.Salvadori, C.Bianchi, R.Tomatis, M.Attila, L.H.Lazarus
J. Med. Chem. 40, 1997, 2579-2587

29) Design and solution structure of a partially rigid opioid antagonist lacking the basic center. Models of antagonism
O.Crescenzi, F.Fraternali, D.Picone, T.Tancredi, G.Balboni, *R.Guerrini*, L.H.Lazarus, S.Salvadori, P.A.Temussi
Eur. J. Biochem. 247, 1997, 66-73

30) Evolution of the Dmt-Tic pharmacophore: N-terminal methylated derivatives with extraordinary delta opioid antagonist activity
S.Salvadori, G.Balboni, *R.Guerrini*, R.Tomatis, C.Bianchi, S.D.Bryant, P.S.Cooper, L.H.Lazarus
J. Med. Chem. 40, 1997, 3100-3108

31) Synthesis of spinacine and spinacine derivatives: crystal and molecular structures of N^{π}-hydroxymethyl spinacine and N^{α}-methyl spinaceamine
M.Remelli, F.Pulidori, *R.Guerrini*, V.Bertolasi
Journal of Chemical Crystallography 27, 1997, 507-513

32) Design of μ selective opioid dipeptide antagonists
A.Capasso, P.Amodeo, G.Balboni, *R.Guerrini*, L.H.Lazarus, P.A.Temussi, S.Salvadori
FEBS Letters 417, 1997, 141-144

33) Synthesis of glycil-L-spinacine and study of its protonation and Cu (II) complex-formation equilibria in aqueous solution.
C.Conato, M.Remelli, *R.Guerrini*, F.Pulidori
Annali di Chimica 88, 1998, 91-102

34) Rational design of dynorphin A analogues with δ-receptor selectivity and antagonism for δ and k-receptors
R.Guerrini, A.Capasso, M.Marastoni, S.D.Bryant, P.S.Cooper, L.H.Lazarus, P.A.Temussi, S.Salvadori
Bioorg. Med. Chem. 6, 1998, 57-62

35) A new selective antagonist of the nociceptin receptor
R.Guerrini, G.Calò, A.Rizzi, R.Bigoni, C.Bianchi, S.Salvadori, D.Regoli
Br. J. Pharmacol. 123, 1998, 163-165

36) Effect of δ-opioid receptor agonist deltorphin on circulating concentrations of luteinizing hormone and follicle stimulating hormone in healthy fertile women
M.Bondanelli, M.R.Ambrosio, P.Franceschetti, *R.Guerrini*, A.Valentini, E.C.degli Uberti
Human Reproduction 13, 1998, 1159-1162

37) Identification of an immunodominant IgE epitope of the Parietaria judaica major allergene
P.Colombo, D.Kennedy, T.Ramsdale, M.A.Costa, G.Duro, V.Izzo, S.Salvadori, *R.Guerrini*, R.Cocchiara, M.G.Mirisola, S.Wood, D.Geraci
J.of Immunology 160, 1998, 2780-2785

38) High structural side chain specificity required at the second position of immunogenic peptides to obtain stable MHC/peptide complexes
R.Gavioli, *R.Guerrini*, M.G.Masucci, R.Tomatis, S.Traniello, M.Marastono
FEBS letters 421, 1998, 95-99

39) Design of δ-opioid peptide antagonists for emerging drug applications
L.H.Lazarus, S.D.Bryant, P.S.Cooper, *R.Guerrini*, G.Balboni, S.Salvadori
Drug Discovery Today 3, 1998, 284-294

40) Pharmacological characterization of the nociceptin receptor mediating hyperalgesia in the mouse tailwithdrawal assay
G.Calò, A.Rizzi, G.Marzola, *R.Guerrini*, S.Salvadori, L.Beani, D.Regoli, C.Bianchi
Br. J. Pharmacol.125, 1998, 373-378

41) Structure-activity study of the nociceptin (1-13)-NH_2 N-terminal tetrapeptide and discovery of a nociceptin receptor antagonist
G.Calò, *R.Guerrini*, R.Bigoni, A.Rizzi, C.Bianchi, D.Regoli, S.Salvadori
J. Med. Chem.41, 1998, 3360-3366

42) Nociceptin receptor binding in mouse forebrain membranes: thermodynamic characteristics and structure activity relationships
K.Varani, G.Calò, A.Rizzi, S.Merighi, G.Toth, *R.Guerrini*, S.Salvadori, P.A.Borea, D.Regoli
Br. J. Pharmacol. 125, 1998, 1485-1490

43) A single specific amino acid residue in peptide antigens is sufficient to activate memory CTL: potential role of cross-reactive peptides in memory T cell maintenance
E.Reali, *R.Guerrini*, M.Marastoni, R.Tomatis, M.G.Masucci, S.Traniello, R.Gavioli
J . of Immunology 162, 1999, 106-113

44) Cardiovascular effects of nociceptin in unanesthetized mice
P.Madeddu, M.B.Salis, A.F.Milia, C.Emanueli, *R.Guerrini*, D.Regoli, G.Calò
Hypertension 33, 1999, 914-919

45) Opioid deltorphin C analogues containing cis- or trans-2- or 3- or 4-aminocyclohexanecarboxylic acid residues

M.Marastoni, *R.Guerrini*, G.Balboni, S.Salvadori, G.Fantin, M.Fogagnolo, L.H.Lazarus, R.Tomatis
Arzneim. Forsch. Drug Res. 49, 1999, 6-12

46) Nociceptin receptor activation inhibits tachykinergic non adrenergic non cholinergic contraction of guinea pig isolated bronchus
A.Rizzi, G.Calò, M.Trevisani, M.Tognetto, L.Fabbri, C.Mapp, *R.Guerrini*, S.Salvadori, D.Regoli, P.Geppetti
Life Sciences 64, 1999, PL 157-163

47) Tritiation of delta opioid-receptor selective antagonist dipeptide ligand with extraordinary affinity containing 2',6' dimethyltyrosine
I.Kertesz, G.Toth, G.Balboni, *G.Guerrini*, S.Salvadori
Czechoslovak Journal of Phisics 49, 1999, 887-892

48) Characterization of nociceptin receptors in the periphery: in vitro and in vivo studies
R.Bigoni, S.Giuliani, G.Calò, A.Rizzi, *R.Guerrini*, S.Salvadori, D.Regoli, C.A.Maggi
Naunyn-Schmiedeberg's Arch. Pharmacol. 359, 1999, 160-167

49) Comparison of the effects of [Phe$^1\psi$(CH_2NH)Gly^2]Nociceptin(1-13)NH_2 in rat brain, rat vas deferens and CHO cells expressing recombinant human ORL1 receptors
H.Okawa, B.Nicol, R.Bigoni, R.A.Hirst, G.Calò, *R.Guerrini*, D.J.Rowbotham, D.Smart, A.T.McKnight, D.G.Lambert
Br. J. Pharmacol. 127, 1999, 123-130

50) Selective amino acid modifications of a subdominant Epstein-Barr virus LMP2-derived epitope increase HLA/peptide complex stability and immunogenicity: implications for immunotherapy of Epstein-Barr virus associated malignancies
F.Micheletti, *R.Guerrini*, A.Formentin, M.Marastoni, R.Tomatis, S.Traniello, R.Gavioli
Eur J Immunol. 29, 1999, 2579-2589.

51) Pharmacology of [Tyr1]nociceptin analogs: receptor binding and bioassay studies.
K.Varani, A.Rizzi, G.Calò, R.Bgoni, G.Toth, *R.Guerrini*, S.Gessi, S.Salvadori, P.A.Borea, D.Regoli
Naunyn Schmiedebergs Arch Pharmacol. 360, 1999, 270-277.

52) Nociceptin binding sites in frog (Rana esculenta) brain membranes.
S.Benyhe, K.Monory, J.Farkas, G.Toth, *R.Guerrini*, S.Salvadori, G.Orosz, M.Wollemann, A.Borsodi
Biochem Biophys Res Commun. 260, 1999, 592-596.

53) L-Glutamate and gamma-Aminobutyric Acid Efflux from Rat
Cerebrocortical Synaptosomes: Modulation by kappa- and
mu- but not delta- and Opioid Receptor Like-1 Receptors.
S.Sbrenna, M.Marti, M.Morari, G.Calo, *R.Guerrini*, L.Beani, C.Bianchi
J Pharmacol Exp Ther. 291, 1999, 1365-1371

54) Further studies on the Dmt-Tic pharmacophore: hydrophobic substituents at the C-terminus endow δ antagonists to manifest μ agonism or μ antagonism
S.Salvadori, *R.Guerrini*, G.Balboni, C.Bianchi, S.D.Bryant, P.S.Cooper, L.H.Lazarus
J. Med. Chem.42, 1999, 5010-5019

55) [Nphe^1]nociceptin(1-13)NH_2 antagonizes nociceptin effects in the mouse colon
A.Rizzi, R.Bigoni, G.Calò, *R.Guerrini*, S.Salvadori, D.Regoli
Eur. J. Pharm. 385, 1999, R3-R5

56) Structure activity studies on nociceptin/orphanin FQ: from full agonist, to partial agonist, to pure antagonist
S.Salvadori, *R.Guerrini*, G.Calò, D.Regoli
Il Farmaco 54, 2000, 810-825

57) Antagonistic effects of [Nphe^1]nociceptin(1-13)NH_2 on nociceptin receptor mediated inhibition of cAMP formation in Chinese ovary hamster cells stably expressing the recombinant human nociceptin receptor
Y.Hashimoto, G.Calò, *R.Guerrini*, G.Smith, D.G.Lambert
Neuroscience Letters 278, 2000, 109-112

58) Pharmacological characterization of the nociceptin receptor mediating hyperphagia: identification of a selective antagonist
C.Polidori, G.Calò, R.Ciccocioppo, *R.Guerrini*, D.Regoli, M.Massi
Psychopharmacology 148, 2000, 430-437

59) Presence and bronchomotor activity of protease activated receptor-2 (PAR-2) in guinea pig airwais
F.Ricciardolo, M.Steinhoff, S.Amadesi, *R.Guerrini*, M.Tognetto, M.Trevisani, C.Creminon, C.Bertrand, N.W.Bunnett, L.M.Fabbri, S.Salvadori, P.Geppetti
Am.J.Respir.Crit.Care Med. 161, 2000, 1672-1680

60) Characterization of [Nphe^1]nociceptin(1-13)NH_2, a new selective nociceptin receptor antagonist
G.Calò, *R.Guerrini*, R.Bigoni, A.Rizzi, G.Marzola, H.Okawa, C.Bianchi, D.G.Lambert, S.Salvadori, D.Regoli
Br.J.Pharmacol. 129, 2000, 1183-1193

61) Modulation of 5-hydroxytryptamine efflux from rat cortical synaptosomes by opioids and nociceptin
S.Sbrenna, M.Marti, M.Morari, G.Calò, *R.Guerrini*, L.Beani, C.Bianchi
Br.J.Pharmacol. 130, 2000, 425-433

62) Supraspinal and spinal effects of [Phe$^1\psi(CH_2NH)$Gly^2]Nociceptin(1-13)NH_2 on nociception in the rat
S.Candeletti, *R.Guerrini*, G.Calò, P.Romualdi, S.Ferri
Life Sciences 66, 2000, 257-264

63) Pharmacology of nociceptin and its receptor: a novel therapeutic target
G.Calò, *R.Guerrini*, A.Rizzi, S.Salvadori, D.Regoli
Br.J.Pharmacol. 129, 2000, 1261-1283

64) Solution structure of nocistatin, a new peptide analgesic
O.Crescenzi, *R.Guerrini*, D.Picone, S.Salvadori, T.Tancredi, P.A.Temussi

Biopolymers 53, 2000, 257-264

65) In vitro characterization of J-113397, a non peptide nociceptin/orphanin FQ receptor antagonist
R.Bigoni, G.Calò, A.Rizzi, *R.Guerrini*, C.De Risi, Y.Hashimoto, E.Hashiba, D.G.Lambert, D.Regoli
Naunyn Schmiedebergs Arch Pharmacol. 361, 2000, 565-568.

66) [Nphe^1]nociceptin(1-13)NH_2 selectively antagonizes nociceptin effects in the rabbit isolated ileum
L.H.Pheng, G.Calò, *R.Guerrini*, D.Regoli
Eur. J. Pharm. 397, 2000, 383-388

67) Pain peptides. Solution structure of orphanin FQ
P.Amodeo, B.L.Mendez, *R.Guerrini*, S.Salvadori, P.A.Temussi, T.Tancredi
FEBS letters 473, 2000, 157-160

68) [Nfhe^1]NC(1-13)NH_2 selectively antagonizes Nociceptin/Orphanin FQ-Stimulated G-protein activation in rat brain
H.Berger, G.Calò, E.Albrecht, *R.Guerrini*, M.Bienert
J Pharmacol Exp Ther. 294, 2000, 428-433

69) The Nociceptin/Orphanin FQ receptor antagonist, [Nfhe^1]NC(1-13)NH_2, potentiates morphine analgesia
A.Rizzi, R.Bigoni, G.Marzola, *R.Guerrini*, S.Salvadori, D.Regoli, G.Calò
Neuroreport, 11, 2000, 2369-2372

70) Further studies on Nociceptin-Related peptides: discovery of a new chemical template with antagonist activity on the nociceptin receptor
R.Guerrini, G.Calò, R.Bigoni, A.Rizzi, K.Varani, G.Toth, S.Gessi, E.Hashiba, Y.Hashimoto, D.G.Lambert, P.A.Borea, R.Tomatis, S.Salvadori, D.Regoli
J. Med. Chem. 43, 2000, 2805-2813

71) Characterization of N,N(Me)$_2$-Dmt-Tic-OH, a delta selective opioid dipeptide antagonist
K.Monory, S.D.Bryant, I.Kertesz, G.Balboni, *R.Guerrini*, G.Toth, S.Salvadori, L.H.Lazarus, A.Borsodi
Neuroreport, 11, 2000, 2083-2086

72) Identification of a novel 45 Kda protein from rabbit sarcoplasmic-reticulum junctional-face membrane
F.Zorzato, A.Anderson, K.Ohlendieck, G.Froemming, *R.Guerrini*, S.Treves
Biochem. J., 351, 2000, 537-543

73) Evidence that PAR-1 and PAR-2 mediate prostanoid-dependent contraction in isolated guinea-pig gallbladder
M.Tognetto, M.Trevisani, B.Maggiore, G.Navarra, A.Turini, *R.Guerrini*, N.W.Bunnett, P.Geppetti, S.Harrison
Br.J.Pharmacol. 131, 2000, 689-694

74) Inverse agonism by Dmt-Tic analogues and HS 378, a naltrindole analogue

M.Labarre, J.Butterworth, S..St-Onge, K..Payza, H.Schimidhammer, S.Salvadori, G.Balboni, *R.Guerrini*, S.D.Bryant, L.H.Lazarus
Eur.J.Pharmacol., 406, 2000, R1-R3

75) Structure-activity relationship of nociceptin and related peptides: comparison with dynorphin A
R.Guerrini, G.Calò, A.Rizzi, R.Bigoni, D.Rizzi, D.Regoli, S.Salvadori
Peptides, 21, 2000, 923-933

76) Nociceptin/orphanin FQ receptor ligands
G.Calò, R.Bigoni, A.Rizzi, *R.Guerrini*, S.Salvadori, D.Regoli
Peptides, 21, 2000, 935-947

77) Studies of the cardiovascular effects of nociceptin and related peptides
M.B.Salis, C.Emanueli, A.F.Milia, *R.Guerrini*, P.Madeddu
Peptides, 21, 2000, 985-993

78) Opioid pseudopeptides containing heteroaromatic or heteroaliphatic nuclei
G.Balboni, S.Salvadori, *R.Guerrini*, C.Bianchi, V.Santagada, G.Calliendo, S.D.Bryant, L.H.Lazarus
Peptides, 21, 2000, 1663-1671

79) Parallel bioassay of 39 tachykinins on 11 smooth muscle preparations. Structure and receptor selectivity/affinity relationship
C.Severini, S.Salvadori, *R.Guerrini*, G.Falconieri-Erspamer, G.Mignogna G.Erspamer
Peptides, 21, 2000, 1587-1595

80) [Nphe^1]NC(1-13)NH_2, a nociceptin receptor antagonist, reverses nociceptin-induced spatial memory impairments in the Morris water maze task in rats
J.P.Redrobe; G.Calò; *R.Guerrini*; D.Regoli; R.Quirion
Br.J.Pharmacol. 131, 2000, 1379-1384

81) Nociceptin/orphanin FQ inhibits ischaemia-induced glutamate efflux from rat cerebrocortical slices
R.M.Nelson; G.Calò; *R.Guerrini*; A.H.Hainsworth; A.R.Green; D.G.Lambert
Neuroreport, 11, 2000, 3689-3692

82) Assessment of substitution in the second pharmacophore of Dmt-Tic analogues
V.Santagada, G.Balboni, G.Caliendo, *R.Guerrini*, S.Salvadori, C.Bianchi, S.D.Bryant, L.H.Lazarus
Bioorg. Med. Chem. Lett. 10, 2000, 2745-2748

83) Characterisation and comparison of novel ligands for the nociceptin/orphanin FQ receptor
E.Hashiba, C.Harrison, G.Calò, *R.Guerrini*, D.J.Rowbotham, G.Smith, D.G.Lambert
Naunyn Schmiedebergs Arch Pharmacol. 362, 2001, 28-33

84) Characterization of the locomotor activity-inhibiting effect of nociceptin/orphanin FQ in mice
A.Rizzi, R.Bigoni, G.Marzola, *R.Guerrini*, S.Salvadori, D.Regoli, G.Calò
Naunyn Schmiedebergs Arch Pharmacol. 363, 2001, 161-165

85) Effect of nociceptin and endomorphin I on the electrically stimulated human vas deferens
R.Bigoni, G.Calò, *R.Guerrini*, J.W.Strupish, D.J.Rowbotham, D.G.Lambert
Br.J.of Clin.Pharmacol. 51, 2001, 355-358

86) Structure activity relationships of the [Nphe^1]NC(1-13)NH_2, a pure and selective nociceptin/orphanin FQ receptor antagonist
R.Guerrini, G.Calò, R.Bigoni, D.Rizzi, D.Regoli, S.Salvadori
J. Peptide Res. 57, 2001, 215-222

87) Nociceptin/OrphaninFQ exacerbates excitotoxic white-matter lesions in the murine neonatal brain
V.Laudenbach, G.Calò, *R.Guerrini*, G.Lamboley, J.F.Benoist, P.Evrard, P.Gressens
J.Clin.Investig. 107, 2001, 457-466

88) Effects of nociceptinNH2 and [Nphe1]nociceptin(1-13)NH_2 on rat brain noradrenaline release in vivo and in vitro.
H. Okawa, M. Kudo, T. Kudo, *R. Guerrini*, D. G. Lambert, T. Kushikata, H.Yoshida, A. Matsuki.
Neuroscience Lett. 303, 2001, 173-176

89) Effects of Ro 64-6198 in nociceptin/orphanin FQ-sensitive isolated tissues
D.Rizzi, R.Bigoni, A.Rizzi, F.Jenck, J.Wichmann, *R.Guerrini*, D.Regoli, G.Calò
Naunyn Schmiedebergs Arch Pharmacol. 363, 2001, 551-555

90) Immunosensing by a synthetic ligand-gated ion channel
S.Terrettaz, W.P.Ulrich, *R.Guerrini*, A.Verdini, H.Vogel
Angew. Chem. Int. Ed. 40, 2001, 1740-1743

91) Copper complexes of glycyl-histidyl-lysine and two of its synthetic analogues: chemical behaviour and biological activity
C.Conato, R.Gavioli, *R.Guerrini*, H.Kozlowski, P.Mlynarz, C.Pasti, F.Pulidori, M.Remelli
Biochim. Biophys. Acta 1526, 2001, 199-210

92) Inhibition of human multidrug resistence P-glycoprotein 1 by analogues of a potent δ-opioid antagonist
T.Lovekamp, P.S.Cooper, J.Hardison, S.D.Bryant, *R.Guerrini*, G.Balboni, S.Salvadori, L.H.Lazarus
Brain Research 902, 2001, 131-134

93) Endogenous nociceptin signaling and stress-induced analgesia
A.Rizzi, G.Marzola, R.Bigoni, *R.Guerrini*, S.Salvadori, J.S.Mogil, D.Regoli, G.Calò
Neuroreport 12, 2001, 3009-3013

94) Urodynamic and clinical evidence of acute inhibitory effects of intravesical nociceptin/orphanin FQ on detrusor overactivity in humans: a pilot study
M.Lazzeri, G.Calò, M.Spinelli, *R.Guerrini*, P.Beneforti, S.Sandri, A.Zanollo, D.Regoli, D.Turini
J. of Urology 166, 2001 2237-2240

95) Structure-activity studies of the Phe^4 residue of nociceptin(1-13)-NH_2: identification of highly potent agonists of the nociceptin/orphanin FQ receptor
R.Guerrini, G.Calò, R.Bigoni,D.Rizzi, A.Rizzi, M.Zucchini, K.Varani, E.Hashiba, D.G.Lambert, G.Toth, P.A.Borea, S.Salvadori, D.Regoli
J.Med.Chem. 44, 2001, 3956-3964

96) Studies on the nociceptive effect of [Nphe1]nociceptin(1-13)NH_2 in mice
A.Di Giannuario, A.Rizzi, S.Pieretti, *R.Guerrini*, R.Bertorelli, S.Salvadori, D.Regoli, G.Calò
Neuroscience Letters 316, 2001, 25-28

97) [$Nphe^1$]N/OFQ-(1-13)-NH_2 is a competitive and selective antagonist at nociceptin/orphanin FQ receptors mediating KM^+ chanel activation in rat periaqueductal gray slices
L.C.Chiou, S.H.Fan, *R.Guerrini*, G.Calò
Neuropharmacology 42, 2002, 246-252

98) Intrathecal [Nphe1]nociceptin(1-13)NH_2 selectively reduces the spinal inhibitory effect of nociceptin
I.S.Xu, S.Grass, G.Calò, *R.Guerrini*, Z.Wiesenfeld-Hallin, X.J.Xu
Life Sciences 70, 2002, 1151-1157

99) Pharmacological characterization of the nociceptin receptor which mediates reduction of alcohol drinking in rats
R.Ciccocioppo, C.Polidori, L.Antonelli, S.Salvadori, *R.Guerrini*, M.Massi
Peptides 23, 2002, 117-125

100) [Arg14, Lys15]Nociceptin, a highly potent agonist of the nociceptin/orphanin FQ receptor: in vitro and in vivo studies
D.Rizzi, A.Rizzi, R.Bigoni, V.Camarda, G.Marzola, *R.Guerrini*, C.De Risi, D.Regoli G.Calò
J Pharmacol Exp Ther. 300, 2002, 57-63

101) Evaluation of the Dmt-Tic pharmacophore: convertion of a potent δ-Opioid receptor antagonist into a potent δ-Agonist and ligands with mixed properties
G.Balboni, *R.Guerrini*, S.Salvadori, C.Bianchi, D.Rizzi, S.D.Bryant, L.H.Lazarus
J.Med.Chem. 45, 2002, 713-720

102) Nociceptin/orphanin FQ receptors modulate glutamate extracellular levels in the substantia nigra pars reticulata. Microdialysis study in the awake freely moving rat
M.Marti, *R.Guerrini*, L.Beani, C.Bianchi, M.Morari
Neuroscience 112, 2002, 153-160

103) Pharmacological profile of nociceptin/orphanin FQ receptors
G.Calò, A.Rizzi, R.Bigoni, *R.Guerrini*, S.Salvadori, D.Regoli
Clin. Exp. Pharmacol. Physiol. 29, 2002, 223-228

104) [$Nphe^1$, Arg^{14}, Lys^{15}]Nociceptin-NH_2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor
G.Calò, A.Rizzi, D.Rizzi, R.Bigoni, *R.Guerrini*, G.Marzola, M.Marti, J.McDonald, M.Morari, D.G.Lambert, S.Salvadori, D.Regoli
Br.J.Pharmacol. 136, 2002, 303-311

105) Effects of [(pF)Phe^4]nociceptin/orphanin FQ-(1-13)NH_2 on GTPγ^{35}S binding and cAMP formation in Chinese hamster ovary cells expressing the human nociceptin/orphanin FQ receptor
J.McDonald, T.A.Barnes, G.Calò, *R.Guerrini*, D.J.Rowbotham, D.G.Lambert
Eur.J.Pharmacol. 443, 2002, 7-12

106) The SH3 domain of nebulin binds selectively to type II peptides: theoretical prediction and experimental validation
A.S.Politou, R.Spadaccini, C.Joseph, B.Brannetti, *R.Guerrini*, M.Helmer-Citterich, S.Salvadori, P.A.Temussi, A.Pastore
J.Mol.Biol. 316, 2002, 305-315

107) Pharmacological profile of hemokinin 1: a novel member of the tachykinin family
V.Camarda, A.Rizzi, G.Calò, *R.Guerrini*, S.Salvadori, D.Regoli
Life Science 71, 2002, 363-370

108) Pharmacological characterization of [(pX)Phe4]nociceptin(1-13)amide analogues: I) in vitro studies
R.Bigoni, D.Rizzi, A. Rizzi, V. Camarda, *R. Guerrini*, D.G.Lambert, E.Hashiba, H. Berger, S. Salvadori, D. Regoli, G. Calo'
Naunyn Schmiedebergs Arch Pharmacol. 365, 2002, 442-449

109) Pharmacological characterization of [(pX)Phe4]nociceptin(1-13)amide analogues: II) in vivo studies
A.Rizzi, M.B.Salis, R.Ciccocioppo, G.Marzola, R.Bigoni, *R.Guerrini*, M.Massi, P.Madeddu, S.Salvadori, D.Regoli, G.Calò
Naunyn Schmiedebergs Arch Pharmacol. 365, 2002, 450-456

110) Solution structure of nociceptin peptides
P.Amodeo, *R.Guerrini*, D.Picone, S.Salvadori, R.Spadaccini, T.Tancredi, P.A.Temussi
J. Peptide Sci. 8, 2002, 497-509

111) Central injections of nocistatin or its C-terminal hexapeptide exert anxiogenic-like effect on behaviour of mice in the plus-maze test
E.C.Gavioli, G.A.Rae, G.Calò, *R.Guerrini*, T.C.M.De Lima
Br.J.Pharmacol. 136, 2002, 764-772

112) Effects of chronic nociceptin/orphanin FQ exposure on cAMP accumulation and receptor density in Chinese hamster ovary cells expressing human nociceptin/orphanin FQ receptors
Y.Hashimoto, G.Calò, *R.Guerrini*, G.Smith, D.G.Lambert
Eur.J.Pharmacol. 449, 2002, 17-22

113) A new ligand for the urotensin II receptor
V.Camarda, *R.Guerrini*, E.Kostenis, A.Rizzi, G.Calò, A.Hattenberger, M.Zucchini, S.Salvadori, D.Regoli
Br.J.Pharmacol. 137, 2002, 311-314

114) Cryatal structures of dipeptides containing the Dmt-Tic pharmacophore
S.D.Bryant, C.George, J.L.Flippen-Anderson, J.R.Deshanps, S.Salvadori, G.Balboni, *R.Guerrini*, L.H.Lazarus

J.Med.Chem. 45, 2002, 5506-5513

115) Potent δ opioid receptor agonists containig the Dmt-Tic pharmacophore
G.Balboni, S.Salvadori, *R.Guerrini*, L.Negri, E.Giannini, Y.Jinsmaa, S.D.Bryant, L.H.Lazarus
J.Med.Chem. 45, 2002, 5556-5563

116) Solution structure of the Alzheimer amyliod b-peptide (1-42) in an apolar microenvironment
O.Crescenzi, S.Tomaselli, *R.Guerrini*, S.Salvadori, A.M.D'Ursi, P.A.Temussi, D.Picone
Eur. J. Biochem. 269, 2002, 5642-5648

117) Nociceptin/orphanin FQ(1-13)NH_2 analogues modified in the Phe^1-Gly^2 peptide bond
R.Guerrini, D.Rizzi, M.Zucchini, R.Tomatis, D.Regoli, G.Calò, S.Salvadori
Bioorg. Med. Chem. Lett.13, 2003, 365-368

118) UFP-101, a high affinity antagonist for the nociceptin/orphanin FQ receptor: radioligand and GTPγ35S binding studies
J.McDonald, G.Calò, *R.Guerrini,* D.G.Lambert
Naunyn Schmiedebergs Arch Pharmacol. 367, 2003, 183-187

119) Effects of nociceptin/orphanin FQ receptor ligands on blood pressure, heart rate, and plasma catecholamine concentrations in guinea pigs
E.Hashiba, K.Hirota, T.Kudo, G.Calò, *R.Guerrini*, A.Matsuki
Naunyn Schmiedebergs Arch Pharmacol. 367, 2003, 342-347

120) Pharmacological profiles of presynaptic nociceptin/orphanin FQ receptors modulating 5-hydroxytryptamine and noradrenaline release in the rat neocortex
M.Marti, S.Stocchi, F.Paganini, F.Mela, C.De Risi, G.Calò, *R.Guerrini*, T.A.Barnes, D.G.Lambert, L.Beani, C.Bianchi, M.Morari
Br.J.Pharmacol. 138, 2003, 91-98

121) Urodynamic effects of intravesical nociceptin/orphanin FQ in neurogenic detrusor overactivity: a randomized, placebo-controlled, double-blind study
M.Lazzeri, G.Calò, M.Spinelli, *R.Guerrini*, S.Salvadori, P.Beneforti, S.Sandri, D.Regoli, D.Turini
Urology 61, 2003, 946-950

122) Proteinase-activated receptor-1 (PAR-1) activation contracts the isolated human renal artery in vitro
M.Tognetto, M.R.D'Andrea, M.trevisani, *R.Guerrini*, S.Salvadori, L.Spisani, C.Daniele, P.Andrade-Gordon, P.Geppetti, S.Harrison
Br.J.Pharmacol. 139, 2003, 21-27

123) Blockade of nociceptin/orphanin FQ-NOP receptor signalling produces antidepressant-like effects: pharmacological and genetic evidences from the mouse forced swimming test
E.C.Gavioli, G.Marzola, *R.Guerrini*, R.Bertorelli, S.Zucchini, T.C.M De Lima G.A.Rae, S.salvadori, D.Regoli, G.Calò
Eur. J. of Neuroscience 17, 2003, 1987-1990

124) Assessment of the activity of a novel nociceptin/orphanin FQ analogue at recombinant human nociceptin/orphanin FQ receptors expressed in Chinese hamster ovary cells
K.E.Wright, J.McDonald, T.A.Barnes, D.J.Rwbotham, *R.Guerrini*, G.Calò, D.G.Lambert
Neuroscience Letters 346, 2003, 145-148

125) Characterization of nociceptin/orphanin FQ binding sites in dog brain membranes
E.E.Johnson, H.Gibson, B.Nicol, J.Zanzinger, P.Widdowson, M.Hawthorn, G.Toht, J.Farkas, *R.Guerrini*, D.G.Lambert
Anesth. Analg. 97, 2003, 741-747

126) Pharmacological profile of the cyclic nociceptin/orphanin FQ analogues c[$Cys^{10,14}$]N/OFQ(1-14)NH_2 and c[$Nphe^{1}$,$Cys^{10,14}$]N/OFQ(1-14)NH_2
M.Kitayama, T.A.Barnes, G.Carrà, J.McDonald, G.Calò, *R.Guerrini*, D.J.Rowbotham, G.Smith D.G.Lambert
Naunyn Schmiedebergs Arch Pharmacol. 368, 2003, 528-537

127) Synthesis and opioid activity of N,N-Dimethyl-Dmt-Tic-NH-CH(R)-R' analogues: acquisition of potent δ antagonism
G.Balboni, S.Salvadori, *R.Guerrini*, L.Negri, E.Giannini, S.D.Bryant, Y.Jinsmaa, L.H.Lazarus
Bioorg. Med. Chem. 11, 2003, 5435-5441

128) Functional coupling of the nociceptin/orphanin FQ receptor in dog brain membranes
E.E.Johnson, J.McDonald, B.Nicol, *R.Guerrini*, D.G.Lambert
Brain research 1003, 2004, 18-25

129) Copper binding to the neurotoxic peptide PrP106-126: thermodynamic and structural studies
B.Belosi, E.Gaggelli, *R.Guerrini*, H.Kozlowski, M.Luczkowski, F.M.Mancini, M.Remelli, D.Valensin, G.Valensin
ChemBiochem 5, 2004, 349-359

130) Solution structure of ZASP PDZ domain; implications for sarcoma ultrastructure and enigma family redundancy
Y.Au, R.A.Atkinson, *R.Guerrini*, G.Kelly, C.Joseph, S.R.Martin, F.W.Mus, A.Pallavicini, G.Faulkner, A.Pastore
Structure 12, 2004, 611-622

131) Antidepressant-like efects of the nociceptin/orpnanin FQ receptor antagonist UFP-101: new evidences in rat and mice
E.C.Gavioli, C.W.Vaughan, G.Marzola, *R.Guerrini*, V.A.Mitchell, S.Zucchini, T.C.M. De Lima, G.A.Rae, S.Salvadori, D.Regoli, G.Calò
Naunyn Schmiedebergs Arch Pharmacol 369, 2004, 547-553

132) Nonpeptide/peptide chimeric ligands for the nociceptin/orphanin FQ receptor: design, synthesis and in vitro pharmacological activity
R.Guerrini, G.Carrà, G.Calò, C.Trapella, E.Marzola, D.Rizzi, D.Regoli, S.salvadori
J. Peptide Res. 63, 2004, 477-484

133) Gastrointestinal effects of intracerebroventricularly injected nociceptin/orphanin FQ in rats.
M.Broccardo, *R.Guerrini*, C.Petrella, G.Improta

Peptides 25, 2004, 1013-1020

134) Direct influence of C-terminally substituted amino acids in the Dmt-Tic pharmacophore on δ-opioid receptor selectivity and antagonism
G.Balboni, S.Salvadori, *R.Guerrini*, L.Negri, E.Giannini, S.D.Bryant, Y.Jinsmaa, L.H.Lazarus
J. Med. Chem. 47, 2004, 4066-4071

135) Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticolata stimulates nigrostriatal dopaminergic transmission and motor behaviour
M.Marti, F.Mela, C.Veronesi, *R.Guerrini*, S.Salvadori, M.Federici, N.B.Mercuri, A.Rizzi, G.Franchi, L.Beani, C.Bianchi, M.Morari
J. of Neuroscience 24, 2004, 6659-6666

136) Solution structure of amyloid β-peptide (25-35) in different media
A.M.D'Ursi, M.R.Armenante, *R.Guerrini*, S.Salvadori, G.Sorrentino, D.Picone
J. Med. Chem. 47, 2004, 4231-4238

137) Urantide mimics urotensin-II induced calcium release in cells expressing recombinant UT receptors
V.Camarda, W.Song, E.Marzola, M.Spagnol, *R.Guerrini*, S.Salvadori, D.Regoli, J.P.Thomson, D.J.Rowbotham, S.A.Douglas, G.Calo', D.G.Lambert
Eur. J. Pharm. 498, 2004, 83-86

138) Interaction of calmodulin with the phosphofructokinase target sequence
S.R.Martin, R.R.Biekofsky, M.A.Skinner, *R.Guerrini*, S.Salvadori, J.Feeney, P.M.Bayley
FEBS Letters 577, 2004, 284-288

139) Blockade of nociceptin/orphanin FQ transmission in rat substantia nigra reverses haloperidol-induced akinesia and normalizes nigral glutamate release
M.Marti, F.Mela, *R.Guerrini*, G.Calo', C.Bianchi, M.Morari
J. Nerochem. 91, 2004, 1501-1504

140) Urotensin II stimulates plasma extravasation in mice via UT receptor activation
R.Vergura, V.Camarda, A.Rizzi, M.Spagnol, *R.Guerrini*, G.Calo', S.Salvadori, D.Regoli
Naunyn Schmiedebergs Arch Pharmacol 370, 2004, 347-352

141) Nociceptin/orphanin FQ prevents ethanol-induced gastric lesions in the rat
G.Morini, G.De Caro, *R.Guerrini*, M.Massi, C.Polidori
Regulatory Peptides 124, 2005, 203-207

142) Structure-activity relationship study on human urotensin II
R.Guerrini, V.Camarda, E.Marzola, M.Arduin, G.Calò, M.Spagnol, A.Rizzi, S.Salvadori, D.Regoli
J. Peptide Sci. 11, 2005, 85-90

143) [(pF)Phe^4,Arg^{14},Lys^{15}]N/OFQ-NH2 (UFP-102), a highly potent and selective agonist of the nociceptin/orphanin FQ receptor
G:Carra', A..Rizzi, *R.Guerrini*, T.A.Barnes, J.McDonald, C.P.Hebbes, F.Mela, V.A.Kenigs, G.Marzola, D.Rizzi, E.Gavioli, S.Zucchini, D.Regoli, M.Morari, S.Salvadori, D.J.Rowbotham, D.G.Lambert, D.R.Kapusta, G.Calo'
J. Pharmacol. Exp. Ther. 312, 2005, 1114-1123

144) Activation of the nociceptin/orphanin FQ receptor reduces bronchoconstriction and microvascular leakage in a rabbit model of gastroesophageal reflux
B.D'Agostino, G.Marrocco, M.De Nardo, G.Calo', *R.Guerrini*, L.Gallelli, C.Advenier, F.Rossi
Br.J.Pharmacol. 144, 2005, 813-820

145) The interaction of highly helical structural mutants with the NOP receptor discloses the role of the address domain of nociceptin/orphanin FQ
T.Tancredi, G.Carra', *R.Guerrini*, M.Arduin, G.Calo', D.Regoli, S.Salvadori, P.A.Temussi
Chemistry A European Journal 11, 2005, 2061-2070

146) N- and C-terminal modifications of nociceptin/orphanin FQ generate highly potent NOP receptor ligands
R.Guerrini, G.Calo', D.G.Lambert, G.Carra', M.Arduin, T.A.Barnes, J.McDonald, D.Rizzi, C.Trapella, E.Marzola, D.J.Rowbotham, D.Regoli, S.Salvadori
J. Med. Chem. 48, 2005, 1421-1427

147) UFP-101, a peptide antagonist selective for the nociceptin/orphanin FQ receptor
G.Calo', *R.Guerrini*, A.Rizzi, S.Salvadori, M.Burmeister, D.R.Kapusta, D.G.Lambert, D.Regoli
CNS Drug Reviews 11, 2005, 97-112

148) Functional selectivity of nociceptin/orphanin FQ peptide receptor partial agonists on cardiovascular and renal function
D.R.Kapusta, M.A.Burmeister, G.Calo', *R.Guerrini*, H.B.Gottlieb, V.A.Kenigs
J. Pharmacol. Exp. Ther. 314, 2005, 643-651

149) Modeling of overloaded gradient elution of nociceptin/orphanin FQ in reversed-phase liquid chromatography
N.Marchetti, F.Dondi, A.Felinger, *R.Guerrini*, S.Salvadori, A.Cavazzini
J. of Chromatography 1079, 2005, 162-172

150) Tryptophan replacement in the nociceptin/orphanin FQ receptor ligand Ac-RYYRWK-NH_2
G.Carra', G.Calo', B.Spagnolo, *R.Guerrini*, M.Arduin, E.Marzola, C.Trapella, D.Regoli, S.Salvadori
J. Peptide Res. 66, 2005, 39-47

151) Nociceptin/orphanin FQ inhibits electrically induced contractions of the human bronchus via NOP receptor activation
M.Basso, P.A.Risse, E.Naline, G.Calo', *R.Guerrini*, D.Regoli, C.Advenier
Peptides 26, 2005, 1492-1496

152) Nociceptin/orphanin FQ stimulates human monocyte che motaxis via NOP receptor activation
S.Trombella, R.Vergura, S.Falzarano, *R.Guerrini*, G.Calo', S.Spisani
Peptides 26, 2005, 1497-1502

153) Copper-ion interaction with the 106-113 domain of the prion protein: a solution-equilibria study on model peptides
M.Remelli, M.Donatoni, *R.Guerrini*, A.Janicka, P.Pretegiani, H.Kozlowski

Dalton Trans 2005, 2876-2885

154) [Nphe[1],Arg[14],Lys[15]]N/OFQ-NH_2 is a competitive antagonist of NOP receptors in the periaqueductal gray
L.C.Chiou, Y.Y.Liao, *R.Guerrini*, G.Calo'
Eur. J. Pharmacol. 2005, 515, 47-53

155) The effects of [Arg^{14}, Lys^{15}] nociceptin/orphanin FQ, a highly potent agonist of the NOP receptor, on in vitro and in vivo gastrointestinal functions
M.Broccardo, G.Linari, *R.Guerrini*, S.Agostini, C.Petrella, G.Improta
Peptides 26, 2005, 1590-1597

156) Blockade of nociceptin/orphanin FQ transmission attenuate symptoms and neurodegeneration associated with parkinson's disease
M.Marti, F.Mela, M.Fantin, S.Zucchini, J.M.Brown, J.Witta, M.Di Benedetto, B.Buzas, R.K.Reinscheid, S.Salvadori, *R.Guerrini*, P.Romualdi, S.Candeletti, M.Simonato, B.M.Cox, M.Morari
J. Neurosci. 19, 2005, 9591-9601

157) Peripheral mechanisms involved in gastric mucosal protection by intracerebroventricular and intraperitoneal nociceptin in rats
C.Polidori, M.Massi, *R.Guerrini*, D.Grandi, D.Lupo, G.Morini
Endocrinology 146, 2005, 3861-3867

158) Conversion of the potent δ-opioid agonist "H-Dmt-Tic-NH-CH2-Bid" into δ-opioid antagonists by N1-benzoimidazole alkylation
G.Balboni, *R.Guerrini*, S.Salvadori, L.Negri, E.Giannini, S.D.Bryant, Y.Jinsmaa, L.H.Lazarus
J. Med. Chem. 48, 2005, 8112-8114

159) Identification of an achiral analogue of J-113397 as potent Nociceptin/Orphanin FQ receptor antagonist
C.Trapella, *R.Guerrini*, L.Piccagli, G.Calo', G.Carra', B.Spagnolo, S.Rubini, G.Fanton, C.Hebbes, J.McDonald, D.G.Lambert, D.Regoli, S.Salvadori
Bioorg. Med. Chem. 14, 2006, 692-704

160) In vitro and in vivo pharmacological characterization of the novel UT receptor ligand [Pen^5, $DTrp^7$, Dab^8]urotensin II(4-11) (UFP-803)
V.Camarda, M.Spagnol, W.Song, R.Vergura, A.L.Roth, J.P.Thompson, D.J.Rowbotham, *R.Guerrini*, E.Marzola, S.Salvadori, P.Cavanni, D.Regoli, S.A.Douglas, D.G.Lambert, G.Calo'
Br.J.Pharmacol. 147, 2006, 92-100

161) Solution structure of Aβ-(1-42) in aqueous media. The α to β conformational transition of Alzheimer's Aβ-(1-42) peptide in aqueous media is reversible: a step by step conformational analysis suggests the location of the β conformation seeding
S.Tomaselli, V.Esposito, P.Vangone, N.A.J. van Nuland, A.M.J.J.Bonvin, *R.Guerrini*, T.Tancredi, P.A.Temussi, D.Picone
ChemBiochem 7, 2006, 257-267

162) Cationic liposomes as potential carriers for ocular administration of peptides with anti-herpetic activity
R.Cortesi, R.Argnani, E.Esposito, A.Dalpiaz, A.Scatturin, F.Bortolotti, M.Lufino, *R.Guerrini*, G.Cavicchioni, C.Incorvaia, E.Menegatti, R.Manservigi
International J. of Pharmaceutics 317, 2006, 90-100

163) Endogenous nociceptin/orphanin FQ signalling produces opposite spinal antinociceptive and supraspinal pronociceptive effects
A.Rizzi, C.Nazzaro, G.Marzola, S.Zucchini, C.Trapella, *R.Guerrini*, H.U.Zeilhofer, D.Regoli, G.Calo'
PAIN 124, 2006, 100-108

164) Cell and tissue responses of a range of urotensin II analogs at cloned and native urotensin II receptors. Evidence for coupling promiscuity
W.Song, J.McDonald, V.Camarda, G.Calo', *R.Guerrini*, E.Marzola, J.P.Thompson, D.J.Rowbotham, D.G.Lambert
Naunyn Schmiedebergs Arch Pharmacol 373, 2006, 148-157

165) In vitro and in vivo pharmacological characterization of the nociceptin/orphanin FQ receptor ligand Ac-RYYRIK-ol
O.Gunduz, A.Rizzi, A.Baldisserotto, *R.Guerrini*, B.spagnolo, E.C.Gavioli, L.Kocsis, A.Magyar, S.Benyhe, A.Borsodi, G.Calo'
Eur. J. Pharmacol. 539, 2006, 39-48

166) new approaches to high-throughput structure characterization of SH3 complexes: The example of Myosin-3 and Myosin-5 SH3 domains from S. cerevisiae
V.Musi, B.Birdsall, G.Fernandez-Ballester, *R.Guerrini,* S.Salvadori, L.Serrano, A.Pastore
Protein Sci. 15, 2006, 795-807

167) Chronic intracerebroventricular infusion of nociceptin/orphanin FQ increases food and ethanol intake in alcohol-preferring rats.
C.Cifani, *R.Guerrini*, M.Massi, C.Polidori
Peptides 27, 2006, 2803-2810

168) Structure activity studies on neuropeptide S: identification of the aminoacid residues crucial for receptor activation
A.L.Roth, E.Marzola, A.Rizzi, M.Arduin, C.Trapella, C.Corti, R.Vergura, P.Martinelli, S.salvadori, D.Regoli, M.Corsi, P.Cavanni, G.Calo', *R.Guerrini*
J. Biol. Chem. 281, 2006, 20809-20816

169) Daily Intravescical instillation of 1 mg Nociceptin/Orphanin FQ for the control of neurogenic detrusor overactivity a multicenter, placebo controlled, randomized exploratory study
M.Lazzeri, G.Calo', M.Spinelli, S.Malaguti, *R.Guerrini*, S.Salvadori, P.Beneforti, D.Regoli, D.Turini
J. of Urology 176, 2006, 2098-2102

170) Structural and dynamic characterization of Cu(II) binding of the human prion protein (HPrP) outside the octarepeat region
F.Berti, E.Gaggelli, *R.Guerrini*, A.Janicka, H.Kozlowski, A.Lerowska, H.Miecznikowska, C.Migliorini, R.Pogni, M.Remelli, K.Rolka, D.Valensin, G.Valensin

Chemistry A European Journal 13, 2007, 1991-2001

171) UFP-101 antagonizes the spinal antinociceptive effects of nociceptin/orphanin FQ: behavioral and electrophysiological studies in mice
C.Nazzaro, A.Rizzi, S.Salvadori, *R.Guerrini*, D.Regoli, H.U.Zeilhofer G.Calo'
Peptides 28, 2007, 663-669

172) In vitro pharmacological characterization of a novel cyclic nociceptin/orphanin FQ analogue c[$Cys^{7,10}$]N/OFQ(1-13)NH_2
M.Kitayama, J.McDonald, T.A.Barnes, G.Calo', *R.Guerrini*, D.J.Rowbotham, D.G.Lambert
Naunyn Schmiedebergs Arch Pharmacol 375, 2007, 369-376

173) Synthesis and biological activity of nociceptin/orphanin FQ analogues substituted in position 7 or 11 with Cα,α-dialkylated amino acids
M.Arduin, B.Spagnolo, G.Calo', *R.Guerrini*, G.Carra', C.Fischetti, C.Trapella, E.Marzola, J.McDonald, D.G.Lambetr, D.Regoli, S.Salvadori
Bioorg. Med. Chem. 15, 2007, 4434-4443

174) In vitro and in vivo studies on UFP-112, a novel potent and long lasting agonist selective for the nociceptin/orphanin FQ receptor
A.Rizzi, B.Spagnolo, R.D.Wainford, C.Fischetti, *R.Guerrini*, G.Marzola, A.Baldisserotto, S.Salvadori, D.Regoli, D.R.Kapusta, G.Calo'
Peptides 6, 2007, 1240-1251

175) Conformation-activity relationship of Neuropeptide S and some structural mutants: helicity affects their interaction with the receptor
T.Tancredi, *R.Guerrini*, E.Marzola, C.Trapella, G.Calo', D.Regoli, R.K.Reinscheid, V.Camarda, S.Salvadori, P.A.Temussi
J. Med. Chem. 50, 2007, 4501-4508

176) Nociceptin/orphanin FQ prevents gastric damage induced by cold-restraint stress in the rat by acting in the periphery
D.Grandi, E.Solenghi, *R.Guerrini*, C.Polidori, M.Massi, G.Morini
Peptides 28, 2007, 1572-1579

177) The gastric effects of UFP 112, a new nociceptin/orphanin receptor agonist, in physiological and pathological conditions.
M.Broccardo, *R.Guerrini*, G.Morini, C.Polidori, S.Agostini, C.Petrella, G.Improta
Peptides 28, 2007, 1974-1981

178) Pro-inflammatory and vasodilator effects of nociceptin/orphanin FQ (N/OFQ) in the rat mesenteric microcirculation are mediated by histamine
Z.L.S.Brookes, E.N.Stedman, *R.Guerrini*, B.K.Lawton, G.Calo', D.G.Lambert
Am J Physiol Heart Circ Physiol. 293, 2007, 2977-2985

179)Quantitative Study of [(pF)Phe^4,Arg^{14},Lys^{15}]Nociceptin/Orphanin FQ-NH_2 (UFP-102) at NOP Receptors in Rat Periaqueductal Gray Slices
Chia-Ju Kuo, Yan-Yu Liao, *R.Guerrini*, G.Calo', Lih-Chu Chiou
Eur. J. Pharmacol 579, 2008, 110-115

180) Anxiolytic- and antidepressant-like activities of H-Dmt-Tic-NH-CH(CH2-COOH)-Bid (UFP-512), a novel selective delta opioid receptor agonist
R.Vergura, G.Balboni, B.Spagnolo, E.Gavioli, D.G.Lambert, J.McDonald, C.Trapella, D.Regoli, *R.Guerrini*, S.Salvadori, G.Calo'.
Peptides 29, 2008, 93-103

181) Synthesis and biological activity of human neuropeptide S analogues modified in position 2
V. Camarda, C. Trapella, G. Calo', *R. Guerrini*, A. Rizzi, C. Ruzza, S. Fiorini, E. Marzola, R.K. Reinscheid, D. Regoli, S. Salvadori
J. Med. Chem. 51, 2008, 655-658

182) Study of synthetic peptides derived from the PKI55 protein, a protein kinase C modulator, in human neutrophils stimulated by the methyl ester derivative of the hydrophobic N-formyl tripeptide for-Met-Leu-Phe-OH
R. Selvatici, S. Falzarano, L. Franceschetti, A. Mollica, *R. Guerrini*, A. Siniscalchi S. Spisani
FEBS J. 275, 2008, 449-457

183)Structure-activity relationship study of position 4 in the urotensin-II receptor ligand U-II(4-11)
E. Marzola, V.Camarda, M.Batuwangala, D.G.Lambert, G.Calo', *R.Guerrini*, C.Trapella, D.Regoli, R.Tomatis, S.Salvadori
Peptides 29, 2008, 674-679

184) T. Ono, Y. Kawaguchi, M. Kudo, T. Kushikata, E. Hashiba, H. Yoshida, T. Kudo, K. Furukawa, S. A. Douglas, *R. Guerrini,* G. Calo', K. Hirato
Urotensin II evokes neurotransmitter release from rat cerebrocortical slices
Neurosciences Letters 440, 2008, 275-279

185) Neuropeptides S is a stimulatory anxiolytic - a behavioral study in mice
A. Rizzi, R. Vergura, G. Marzola, C. Ruzza, *R. Guerrini*, S. Salvadori, D. Regoli, G. Calo'
Br.J.Pharmacol. 154, 2008, 471-479

186) Nociceptin/Orpanin FQ modulates motor behavior and primary motor cortex output through receptors located in substantia nigra reticulata
M.Marti, R.Viaro, *R.Guerrini*, G.Balboni, M.Morari
Neuropsychopharmacology 2008, 1-15

187) Central and peripheral role of the nociceptin/orphanin FQ system on normal and disturbed colonic motor function and faecal pellet output in the rat
M.Broccardo, S.Agostini, C.Petrella, *R.Guerrini*, G.Improta
Neurogastroenterol. Motil. 20, 2008, 939-948

188) GABAa signalling is involved in N/OFQ anxiolytic-like effects but not in nocistatin anxiogenic-like action as evaluated in the mouse elevated plus maze
E.C.Gavioli, F.S.Duarte, *R.Guerrini*, G.Caló, G.A.Rae, T.C. Monteiro De Lima
Peptides 29,2008, 1404-1412

189) Synthesis and Antimicrobial Activity of Dermaseptin S1 Analogues
D. Savoia, *R. Guerrini*, E. Marzola, S. Salvadori

Bioorg. Med. Chem. 16, 2008, 8205-8209

190) CuII binding sites located at His-111 of the human prion protein: thermodynamic and spectroscopic studies on model peptides
E. Gralka, D. Valensin, E. Porciatti, C. Gajda, E. Gaggelli, G. Valensin, W. Kamysz, R. Nadolny, *R. Guerrini*, D. Bacco, M. Remelli, H. Kozlowski
Dalton Trans. 2008, 5207-5219

191) Structure-activity study at position 3 and 4 of human neuropeptide S
V. Camarda, C.Trapella, G. Calo', *R. Guerrini*, A. Rizzi, C. Ruzza, S. Fiorini, E. Marzola, R.K. Reinsheid, D. Regoli, S. Salvadori
Bioorg. Med. Chem. 16, 2008, 8841-8845

192) Binding of the Novel Radioligand [3H]UFP-101 to Recombinant Human and Native Rat Nociceptin/Orphanin FQ receptors.
M.Ibba, M.Kitayama, J.McDonald, G. Calo', *R.Guerrini*, J. Farkas, G.Toth, D.G.Lambert.
Naunyn Schmiedebergs Arch Pharmacol 378, 2008, 553-561

193) Anxiolytic-like effect of neuropeptide S in the rat defensive burying
G.Vitale, M.Filaferro, V.Ruggieri, S.Pannella, C.Frigeri, A.Rizzi, *R.Guerrini*, G.Calo'
Peptides 29, 2008, 2286-2291

194) The nociceptin/orphanin FQ-NOP receptor antagonist effects on an animal model of sepsis
D. Carvalho, F. Petronilho, F. Vuolo, R:A: Machado, L. Constantino, *R. Guerrini*, G. Calo', E.C. Gavioli, E.L. Streck, F. Dal-Pizzol
Intensive Care Med. 34, 2008, 2284-2290

195) In vitro and in vivo pharmacological characterization of the neuropeptide S receptor antagonist [D-Cys(tBu)^5]Neuropeptide S
V. Camarda, A. Rizzi, C. Ruzza, S. Zucchini, G. Marzola, E. Marzola, *R. Guerrini*, S. Salvadori, R. K. Reinsheid, D. Regoli, G. Calo'
J. Pharmacol. Exp. Ther. 328, 2009, 549-555

196) Neuropeptide S produces hyperlocomotion and prevents oxidative stress damage in the mouse brain: a comparative study with amphetamine and diazepam
A.A. Castro, M. Moretti, T.S. Casagrande, C. Martinello, F. Petronilho, F. Sterckert, A. V. Dal-Pizzol, G. Calo', *R. Guerrini*, J. Quevedo, E. C. Gavioli
Biochemistry and Behaviour 91, 2009,636-642

197) Synthesis and biological activity of human neuropeptide S analogues modified in position 5: identification of potent and pure neuropeptide S receptor antagonists
R. Guerrini, V. Camarda, C. Trapella, G. Calo', A. Rizzi, C. Ruzza, S. Fiorini, E. Marzola, R. K. Reinscheid, D. Regoli, S. Salvadori
J. Med. Chem. 52, 2009, 524-529

198) Further studies on the pharmacological features of the nociceptin/orphanin FQ receptor ligand ZP120
C. Fischetti, A. Rizzi, E.C. Gavioli, G. Marzola, C.Trapella, *R. Guerrini*, J.S. Petersen, G. Calo'
Peptides 30, 2009, 248-255

199) Pharmacological profile of NOP receptors couplet with calcium signaling via the chimeric protein Galpha(qi5)
V. Camarda, C. Fischetti, N. Anzelotti, P. Molinari, C. Ambrosio, E. Kostenis, D. Regoli, C. Trapella, *R. Guerrini*, S. Salvadori, G. Calo'
Naunyn Schmiedebergs Arch. Pharmacol. 379, 2009, 599-607

200) Perspectives of Protein Kinase C (PKC) Inhibitors as Anti-Cancer Agents
A. Gonelli, C. Mischiati, *R. Guerrini*, R. Voltan, S. Salvadori, G. Zauli
Mini Rev. Med. Chem. 4, 2009, 498-509

201) The hypothalamus-pituitary-adrenal axis does not influence the protective effects of nociceptin orphanin FQ on the rat gastric mucosa
D. Grandi, E. Solenghi, *R. Guerrini*, M. Broccardo, S. Agostani, C. Putrella, S. Scaccianoce, G. Improta, G. Morini
Regulatory Peptides 154, 2009, 32-38

202) Structure-activity relationship study on Tyr9 of urotensin-II(4-11): identification of a partial agonist of the UT receptor
M. Batuwangala, V. Camarda, J. McDonald, E. Marzola, D.G. Lambert, L. L. Ng, G. Calo', D. Regoli, C. Trapella, *R. Guerrini*, S. Salvadori
Peptides 30, 2009, 1130-1136

203) Pharmacological characterization of the nociceptin/orphanin FQ receptor non peptide antagonist Compound 24
C. Fischetti, V. Camarda, A. Rizzi, M. Pela', C. Trapella, *R. Guerrini*, J. McDonald, D. G. Lambert, S. Salvadori, D. Regoli, G. Calo'
Eur. J. Pharmacol 614, 2009, 50-57

204) Further studies at Neuropeptide S position 5: discovery of novel Neuropeptide S receptor antagonists
R. Guerrini, V. Camarda, C. Trapella, G. Calo', A. Rizzi, C. Ruzza, S. Fiorini, E. Marzola, R. K. Reinsheid, D. Regoli, S. Salvadori
J. Med. Chem. 52, 2009, 4068-4071

205) Simultaneous targeting of multiple opioid receptors. A strategy to improve side effect profile.
N. Dietis, *R. Guerrini*, G. Calo, S. Salvadori, D.J. Rowbotham, D.G. Lambert
British Journal of Anaesthesia 103, 2009, 38-49

206) Structure-activity studies on the nociceptin/orphanin FQ receptor antagonist 1-benzyl-N-{3-[spiroisobenzofuran-1(3H),4'-piperidin-1-yl]propyl} pyrrolidine-2-carboxamide
C. Trapella, C. Fischetti, M. Pela, I. Lazzari, *R. Guerrini*, G. Calo, A. Rizzi, V. Camarda D. G. Lambert, J. McDonald, D. Regoli, S. Salvadori
Bioorg. Med. Chem. 17, 2009, 5080-5095

207) Lithium attenuates behavioural and biochemical effects of neuropeptide S in mice
A. Castro, T. Casagrande, M. Moretti, L. Costantini, F. Petronilho, G. Guerra, G. Calo', *R. Guerrini*, F. Dal-Pizzol, J. Quevedo, E. C. Gavioli
Peptides 30, 2009, 1914-1920

208) The paraventricular nucleus of the hypothalamus is a neuroanatomical substrate for the inhibition of palatable food intake by neuropeptide S
A. Fedeli, S. Braconi, D. Economidou, N. Cannella, M. Kallupi, *R. Guerrini*, G. Calo', C. Cifani, M. Massi, R. Ciccocioppo
Eur. J. Neurosci. 30, 2009, 1594-1602

209) Desensitization of native and recombinant human urotensin II receptors
M.S. Batuwangala, G. Calo', *R. Guerrini*, L.L. Ng, J. McDonald, D.G. Lambert
Naunyn Schmiedebergs Arch. Pharmacol. 380, 2009, 451-457

210) The complex-formation behaviour of His residues in the fifth Cu^{2+} binding site of human prion protein: a close look
M. Remelli, D. Valensin, D. Bacco, E. Gralka, *R. Guerrini,* C. Migliorini, H. Kozlowski
New J. Chem. 33, 2009,2300-2310

211) Chronic treatment with the selective NOP receptor antagonist [Nphe1,Arg14,Lys15]N/OFQ-NH2 (UFP-101) reverses the behavioural and biochemical effects of unpredictable chronic mild stress in rats
G. Vitale, V. Ruggeri, M. Filaferro, C. Frigeri, S. Alboni, F. Tascedda, N. Brunello, *R. Guerrini*, C. Cifani, M. Massi
Psychopharmacology 207, 2009, 173-189

212) Emergine evidence for neurotensin receptor 1 antagonists as novel pharmaceutics inneurodegenerative disorders
L. Ferraro, M.C. Tomasini, S. Beggiato, *R. Guerrini*, S. Salvadori, K. Fuxe, L. Calza', S. Tamganelli, T. Antonelli
Mini Rev. Med. Chem. 12, 2009, 1429-1438

213) Neurobiology, phrmacology and medicinal chemistry of neuropeptide S and its receptor
R. Guerrini, S. Salvadori, A. Rizzi, D. Regoli, G. Calo'
Medicinal Research Reviews 30, 2010, 751-777

214) Long lasting antinociceptive spinal effects in primates of the novel Nociceptin/Orphanin FQ receptor agonist UFP-112
E.Hu, G. Calo', *R. Guerrini*, MC Ko
PAIN 148, 2010, 107-113

215) Nociceptin modulates bronchoconstriction induced by sensory nerve activation in mouse lung
B. D'Agostino, D. Orlotti, G. Calo', N. Sullo, M. Russo, *R. Guerrini*, M. De Nardo, F. Mazzeo, S. Candeletti, F. Rossi
Am. J. Respir. Cell. Mol. Biol. 42, 2010, 250-254

216) Blockade of adenosine A2A receptor counteracts neuropeptide S induced hyperlocomotion in mice
C. R. Boeck, C. Martinello, A. A. De Castro, M. Moretti, T. dos Santos Casagrande, *R. Guerrini,* G. Calo', E. C. Gavioli
Naunyn Schmiedebergs Arch. Pharmacol. 381, 2010, 153-160

217) Further studies on the pharmacological profile of the neuropeptide S receptor antagonist SHA 68

C. Ruzza, A. Rizzi, C. Trapella, M. Pela', V. Camarda, V. Ruggeri, M. Filaferro, C. Cifani, R. K. Reinscheid, G. Vitale, R. Ciccocioppo, S. salvadori, R. *Guerrini, G*. Calo'
Peptides 31, 2010, 915-925

218) in vitro activity of dermaseptin S1 derivatives against genital pathogens
D. Savoia, M. Donalisio, A. Civra, S. Salvadori, *R. Guerrini*
APMIS 118, 2010, 674-680

219) Anti-inflammatori and analgesic effects displayed by peptides derived from PK155 protein, an endogenous protein kinase C inhibitor
R. Selvatici, F. Congestri', G. Marzola, *R. Guerrini*, A. Siniscalchi, S. Spisani
Naunyn Schmiedebergs Arch. Pharmacol. 382, 2010, 193-199

220) UFP-112 a potent and long-lasting agonist selective for the nociceptin/orphanin FQ receptor
G. Calo', A. Rizzi, C. Cifani, M. V. Milioni Di Bonaventura, D. Regoli, M. Massi, S. salvatori, D. G. Lambert, *R. Guerrini*
CNS Drug Review 17, 2011, 178-198

221) Effect of Neuropeptide S receptor antagonists and partial agonists on palatable food consumption in rat
C. Cifani, M. V. Micioni Di Bonaventura, N. cannella, A. Fedeli, *R. Guerrini*, G. Calo', R. Ciccocioppo, M. Ubaldi
Peptides 32, 2011, 44-50

222) Synthesis and separation of the enantiomers of the Neuropeptide S receptor antagonist (9R/S)-3-Oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-*a*]pyrazine-7-carboxylic acid 4-fluoro-benzylamide (SHA 68)
C. Trapella, M. Pela', L. Del Zoppo, G. Calo', V. Camarda, C. Ruzza, A. Cavazzini, V. Costa, V. Bertolasi, R. K. Reinscheid, S. Salvadori, *R. Guerrini*
J. Med. Chem. 54, 2011, 2738-2744

223) Neuropeptide S inhibits stress-stimulated faecal output in the rat
C. Petrella, S. Agostini, *R. Guerrini*, G. Calo', A. Giaquinto, C. De Nuccio, G. Improta, M. Broccardo
Pharmacol. Res. 64, 2011, 471-477

224) Protein-protein interface-binding peptides inhibit the cancer target human thymidylate synthase
D. Cardinale, G. Guaitoli, D. Tondi, R. Luciani, S. Henrich, O. Salo-Ahen, S. Ferrarai, G. Marverti, D. Guerrieri, A. Ligabue, C. Frassineti, C. Pozzi, S. Mangani, D. Fessas, *R. Guerrini*, G. Ponterini, R. Wade, P. Costi
PNAS 108, 2011, E542-E549

225) Role of the ecto-nucleotidase in the cooperative effect of adenosine and neuropeptide-S on locomotor activity in mice
R. Pacheco, B. B. Pescador, B. Pescador Medonca, S. F. Ramos, *R. Guerrini*, G. Calo', V. Moreas de Andrade, E. C. Gavioli, C. Rodrigues Boeck.
Pharmacology, Biochemistry and Behavior 99, 2011, 726-730

226) Role of nociceptin/orphanin FQ receptors in the decrease of mucosal mast cells caused by acute stress in the rat colon

D. Grandi, M. Massi, *R. Guerrini*, G. Calo', G. Morini
Life Sci. 89, 2011, 735-740

227) Pharmacological characterization of the bifunctional opioid ligand H-Dmt-Tic-Gly-NH-Bzl (UFP-505)
N. Dietis, J. McDonald, S. Molinari, G. Calo', *R. Guerrini*, D. J. Rowbotham, D. G. Lambert
British Journal of Anaesthesia 108, 2012, 262-270

228) Behavioural phenotypic characterization of CD-1 mice lacking the neuropeptide S receptor
C. Ruzza, A. Pulga, A. Rizzi, G. Marzola, *R. Guerrini*, G. Calo'
Neuropharmacology 62, 2012, 1999-2009

229) [^{t}Bu-D-Gly^{5}]NPS, a pure and potent antagonist of the neuropeptide S receptor: in vitro and in vivo studies
C. Ruzza, A. Rizzi, V. Camarda, A. Pulga, G. Marzola, M. Filaferro, C. Novi, V. Ruggeri, E. Marzola, G. Vitale, S. Salvadori, *R. Guerrini*, G. Calò
Peptides 34, 2012, 404-411

230) Structure of the nociceptin/orphanin FQ receptor in complex with a peptide mimetic
A. A. Thompson, W. Liu, E. Chun, V. Katritch, H. Wu, E. Vardy, X. P. Huang, C. Trapella, *R. Guerrini*, G. Calo, B. L. Roth, V. Cherezov1, R. C. Stevens
Nature 485, 2012, 395-399

231) The role of sulfur of Met residues in Cu(II) binding to the "fifth site" of the human Prion protein: a deeper insight
M. Remelli, L. Toso, D. Valensin, E. Gralka, *R. Guerrini*, H. Kozlowski
Metallomics 4, 2012, 794-806

232) The coordination of Ni2+ and Cu2+ ions to polyhistidyl motif of Hpn protein – is it as strong as we think it is?
D. Witkowska, R. Politano, M. Rowinska-Zyrek, *R. Guerrini*, M. Remelli, H. Kozlowski
Chem. Eur. J. 18, 2012, 11088-11099

233) Anxiolytic- and panicolytic-like effects of Neuropeptide S in the mouse elevated T-maze
A.Pulga, C. Ruzza, A. Rizzi, *R. Guerrini*, G. Calo'
Eur. J. Of Neurosci. 36, 2012, 3531-3537

234) Effects of neuropeptide S on seizures and oxidative damage induced by pentylenetetrazole in mice
S.F. Ramos, B.M. Mendoca, D.D. Leffa, R. Pacheco, A.P. Damiani, G. Hainzenreder, F. Petronlho, F. Dal-Pizzol, *R. Guerrini*, G. Calo', E.C. Gavioli, C.R. Boeck, V. Moraes de Andrade
Pharmacol. Biochem. And Behaviour 103, 2012, 197-203

235) Nociceptin/orphanin FQ receptor agonists attenuate L-DOPA-induced dyskinesias
M. Marti, D. Rodi, Q. Li, *R. Guerrini*, S. Fasano, I. Morella, A. Tozzi, R. Brambilla, P. Calabresi, M. Simonato, E. Bezard, M. Morari
J Neurosci. 32, 2012, 16106-16119

236) Neuropeptide S stimulates human monocyte chemotaxis via NPS receptor activation
M. Filaferro, C. Novi, V. Ruggieri, S. Genedani, S. Alboni, D. Malagoli, G. Caló, *R. Guerrini*, G. Vitale

Peptides 39, 2013, 16-20

237) [Dmt1]N/OFQ(1-13)-NH2, a potent nociceptin/orphanin FQ and opioid receptor universal agonist
S. Molinari, V. Camarda, A. Rizzi, G. Marzola, S. Salvadori, E. Marzola, P. Molinari, J. McDonald, M.C. Ko, D.G. Lambert, G. Calo', *R. Guerrini*
Br. J. Pharmacol. 168, 2013, 151-162

238) Hypothalamic Neuropeptide S receptor blockade decreases discriminative cue-induced reinstatement of cocaine seeking in the rat
M. Kallupi, G. de Guglielmo, N. Cannella, H. Wu Li, G. Caló, *R. Guerrini*, M. Ubaldi, J. J. Ranger, V. N. Uebele, R. Ciccocioppo
Psychopharmacology 226, 2013, 347-355

239) Unexpected impact of the number of glutamine residues on metal complex stability
M.N. Chiera, M. Rowinska-Zyrek, R. Wieczorek, *R. Guerrini*, D. Witkowska, M. Remelli, H. Kozlowski
Metallomics 5, 2013, 214-221

240) In vitro and in vivo pharmacological characterization of the novel neuropeptide S receptor ligands QA1 and PI1
V. Camarda, C. Ruzza, A. Rizzi, C. Trapella, *R. Guerrini*, R. K. Reinscheid, and G. Calo'
Peptides 48, 2013, 27-35

241) Ligands raise the constraint that limits constitutive activation in G protein-coupled opioid receptors.
V. Vezzi,HO Onaran, P. Molinari, *R. Guerrini*, G. Balboni, G. Calo', T. Costa.
J. Biol. Chem. 288, 2013, 23964-23978

242) The Nociceptin/Orphanin FQ Receptor Antagonist UFP-101 Reduces Microvascular Inflammation to Lipopolysaccharide In Vivo
Z. L. S. Brookes , E. N. Stedman, N. J. Brown, C. P. Hebbes, R. Guerrini, G. Calo, C. S. Reilly, D. G. Lambert
Plos One 8, 2013, e74943

243) Nociceptin/orphanin FQ receptor activation decreases the airway hyperresponsiveness induced by allergen in sensitized mice
N. Sullo, F. Roviezzo, M. Matteis, A. Ianaro, G. Calò, R. **Guerrini**, L. De Gruttola, G. Spaziano, G. Cirino, F. Rossi, B. D'Agostino.
Am J Physiol Lung Cell Mol Physiol. 304, 2013, L657–L664.

244) Neuropeptide S: a novel regulator of pain-related amygdala plasticity and behaviors
W. Ren, G. Ji, *R. Guerrini*, G. Calo, V. Neugebauer
J. of Neurophys. 110, 2013, 1765-1781

245) Mixed Tridentate π-Donor and Monodentate π-Acceptor Ligands as Chelating Systems for Rhenium-188 and Technetium-99m Nitrido Radiopharmaceuticals
A. Boschi, L. Uccelli, M. Pasquali, R. Pasqualini, *R. Guerrini*, A. Duatti

Current Radiopharmaceuticals, 2013, 6, 137-145.

246) Neuropeptide S counteracts 6-OHDA-induced motor deficits in mice.
JJ Didonet, JC Cavalcante, LD Souza, MS Costa, E André, VD Soares-Rachetti, *R Guerrini, G* Calo', EC Gavioli
Behav. Brain. Res. 266, 2014, 29-36.

247) Optimization of peptides that target human thymidylate synthase to inhibit ovarian cancer cell growth.
M. Pelà, P. Saxena, R. Luciani, M. Santucci, S. Ferrari, G. Marverti, C. Marraccini, A. Martello, S. Pirondi, F. Genovese, S. Salvadori, D. D'Arca, G. Ponterini, M. P. Costi, *R. Guerrini*
J. Med. Chem. 57,2014, 1355-1367

248) [D-Pen(p-tBuBzl)5]NPS, a novel ligand for the neuropeptide S receptor – structure activity and pharmacological studies
C. Ruzza, L. del Zoppo, D. Malfacini, M. Pela', C. Trapella, P. Grieco, S. Salvadori, G. Calo' *R. Guerrini*
Med. Chem Res. 23, 2014, 3503-3509

249) A novel and facile synthesis of tetra branched derivatives of nociceptin/orphanin FQ
R. Guerrini, E. Marzola, C. Trapella, M. Pela', S. Molinari, M. C. Cerlesi, D. Malfacini, A. Rizzi, S. Salvadori, G. Calo'
Bioorg. Med. Chem. 22, 2014, 3703-3712

250) Racemic synthesis and solid phase peptide synthesis application of the chimeric Valine/Leucine derivative 2-amino-3,3,4-trimethyl-pentanoic acid.
M. Pelà, L. Del Zoppo, L. Allegri, E. Marzola1, C. Trapella, C. Ruzza, G. Calo', E. Perissutti, F. Frecentese, S. Salvadori, *R. Guerrini*
Pharmazie 69, 2014, 469-499

251) Preparation and first biological evaluation of novel Re-188/Tc-99m peptide conjugates with substance-P
K. Smilkov, E. Janevik, *R. Guerrini*, M. Pasquali, A. Boschi, L. Uccelli, G. Di Domenico, A. Duatti
Applied Radiation and Isotopes 92, 2014, 25–31

252) Endogenous neuropeptide S tone influences sleep-wake rhythm in rats
M. Oishi, T. Kushikata, H. Niwa, C. Yakoshi, C. Ogasawara, G. Calo, *R. Guerrini*, K. Hirota
Neurosci.Lett. 581, 2014, 94-97

253) The N-carbamidoyl-4-((3-ethyl-2,4,4-trimethylcyclohexyl)methyl)benzamide enhances Staurosporine cytotoxic effects likely inhibiting the protective action of Magmas towards cell apoptosis.
M. C. Zatelli, T. Gagliano, M. Pela', S. Bianco, V. Bertolasi, F. Tagliati, *R. Guerrini*, E. Degli Uberti, S. Salvadori, C. Trapella
J Med Chem. 57, 2014, 4606-4614

254) Pharmacological characterization of tachykinin tetrabranched derivatives.
C. Ruzza, A. Rizzi, D. Malfacini, M. C. Cerlesi, F. Ferrari, E. Marzola, C. Ambrosio, C. Gro, S. Severo, T. Costa, G. Calo, *R. Guerrini*
Br J Pharmacol. 171, 2014, 4125-4137

255) In vitro and in vivo pharmacological characterization of nociceptin/orphanin FQ tetrabranched derivatives
A Rizzi, D Malfacini, M C Cerlesi, C Ruzza, E Marzola, M F Bird, D J Rowbotham, S Salvadori, *R Guerrini*, D G Lambert, G Calo
Br J Pharmacol. 171, 2014, 4138-4153

256) The internalization and stability of a Thymidylate synthase peptide inhibitor in ovarian cancer cells
G. Canazza, A. Cazzato, C. Marraccini, G. Pavesi, S. Pirondi, *R. Guerrini*, M. Pela, C. Frassineti, G. Marverti, G. Ponterini, M.P. Costi
J. Med. Chem. 57, 2014, 10551−10556

257) Mass spectrometric/bioinformatic identification of a protein subset that characterizes the cellular activity of anticancer peptides
F. Genovese, A. Gualandi, L. Taddia, G. Marverti, S. Pirondi, C. Marraccini, P. Perco, M. Pela, *R. Guerrini*, M.R. Amoroso, F. Esposito, A. Martello, G. Ponterini, D. D'Arca, M.P. Costi
J. Proteome Res. 13, 2014, 5250−5261

258) Central adenosine A1 and A2A receptors mediate the antinociceptive effects of Neuropeptide S in the mouse formalin test
V. A. D. Holanda, L. Asth, A. R Santos, *R. Guerrini*, V. de P. Soares-Rachetti, G. Calo', E. Andre', E. C Gavioli
Life Sciences 120, 2015, 8–12

259) Nociceptin/Orphanin FQ induces simultaneously anxiolytic and amnesic effects in the mouse elevated T maze task
L. Asth, N. Correia, B. Lobao-Soares, T. C. Monteiro de Lima, *R. Guerrini*, G. Calo', V. P. Soares-Rachetti, E. C. Gavioli
Naunyn Schmiedebergs Arch. Pharmacol 388, 2015, 33–41

260) In vitro and in vivo pharmacological characterization of a neuropeptide S tetrabranched derivative
C. Ruzza, A. Rizzi, D. Malfacini, A. Pulga, S. Pacifico, S. Salvadori,C. Trapella, R. K. Reinscheid, G. Calo', *R. Guerrini*
Pharmacology Research & Perspectives 3, 2015, e00108

261) Acute and subchronic antinociceptive effects of nociceptin/orphanin FQ receptor agonists infused by intrathecal route in rats
L. Micheli, L. Di Cesare Mannelli, *R. Guerrini*, C. Trapella, M. Zanardelli, R.Ciccocioppo, A. Rizzi, C. Ghelardini, G. Calò
Eu. J. Pharm. 754, 2015, 73–81

262) Structure activity studies of nociceptin/orphanin FQ(1–13)-NH_2 derivatives modified in position 5
R. Guerrini, E. Marzola, C. Trapella, S. Pacifico, M. C. Cerlesi, D. Malfacini, F. Ferrari, M. F. Bird, D. G. Lambert, S. Salvadori, G. Calo
Bioorg. Med. Chem. 23, 2015, 1515–1520

263) Selective Breeding for High Anxiety Introduces a Synonymous SNP That Increases Neuropeptide S Receptor Activity
D. A. Slattery, R. R. Naik, T. Grund, Yi-Chun Yen, S. B. Sartori, A. Fuchsl, B. C. Finger, B. Elfving, U. Nordemann, *R. Guerrini*, G. Calo, G. Wegener, A. A. Mathe´, N. Singewald, L. Czibere, R. Landgraf, I. D. Neumann
The Journal of Neuroscience 35, 2015, 4599–4613

264) The Development and Characterisation of Novel Fentanyl-Delta Opioid Receptor Antagonist Based Bivalent Ligands.
M. F. Bird, R. Vardanyan, V. Hruby, G. Cal, *R. Guerrini*, S. Salvadori, C. Trapella, J. McDonald, D. J. Rowbotham, D. G. Lambert
British Journal of Anaesthesia 114, 2015, 646–656

265) Physico-chemical stability of cabazitaxel and docetaxel solutions
R. Lazzarini, S. Salvadori, C. Trapella, *R. Guerrini*, E. Marzola, G. Pasini, A. Dalpiaz
European Journal of Hospital Pharmacy 22, 2015, 150-155

266) Nociceptin/orphanin FQ and stress regulate synaptophysin expressionin the rat fundic and colonic mucosa
D. Grandi, G. Becchi, *R. Guerrini*, G. Calò, G. Morini
Tissue and Cell 47, 2015, 147-151

267) Spinal antinociceptive effects of the novel NOP receptor agonist PWT2-nociceptin/orphanin FQ in mice and monkeys.
A. Rizzi, DD. Sukhtankar, H. Ding, K. Hayashida, C. Ruzza, **R. Guerrini**, G. Calo', MC. Ko
Br. J. Pharmacol. 172, 2015, 3661-3670

268) Pharmacological profile of nociceptin/orphanin FQ receptors interacting with G-proteins and -arrestins 2
Malfacini D.; Ambrosio C.; Gro' M. C.; Sbraccia M.; Trapella C.; *Guerrini R*.; Bonora M.; Pinton P.; Costa T.; Calo' G.
PLoS One. 10, 2015, e0132865

269) The importance of ligand-receptor conformational pairs in stabilization: spotlight on the N/OFQ G protein-coupled receptor
R.L Miller., A.A Thompson., C. Trapella, *R. Guerrini*, D. Malfacini, N. Patel, G. W. Han, V. Cherezov, G. Calo´, V. Katritch, R. C. Stevens
Structure 23, 2015, 2291–2299

270) Blockade of nociceptin/orphanin FQ receptor signaling reversesLPS-induced depressive-like behavior in mice
I. U. Medeirosa, C. Ruzza, L. Astha, *R Guerrini*, P. R.T. Romao,Elaine C. Gavioli, G. Calo
Peptides 72, 2015, 95–103

271) Intrathecal administration of nociceptin/orphanin FQ receptor agonists in rats: a strategy to relieve chemotherapy-induced neuropathic hypersensitivity
L. Micheli, L. Di Cesare Mannelli, A. Rizzi, *R. Guerrini*, C. Trapella, G. Calò, C. Ghelardini
Eu. J. Pharmacol. 766, 2015, 155–162

272) Neuropeptide S reduces mouse aggressiveness in the resident/intruder test through selective activation of the neuropeptide S receptor.
C. Ruzza, L. Asth, R. Guerrini, C. Trapella, E. C. Gavioli
Neuropharmacology 97, 2015, 1-6

273) The unusual metal ion binding ability of histidyl tags and their mutated derivatives
D. Brasili, J. Watly, E. Simonovsky, *R. Guerrini*, N. A. Barbosa, R. Wieczorek, M. Remelli, H. Kozlowski, Y. Miller
Dalton Trans 45, 2016, 5629-5639

274) Preferential interaction of the Alzheimer peptide Aβ-(1-42) with Omega-3-containing lipid bilayers: structure and interaction studies.
A. Emendato, R. Spadaccini, A. De Santis, *R. Guerrini,* G. D'Errico, D. Picone
FEBS Lett. 590, 2016, 582-591

275) Design, synthesis and biological characterization of novel mitochondria targeted dichloroacetate-loaded compounds with antileukemic activity
C. Trapella, R. Voltan, E. Melloni, V Tisato, C. Celeghini, S. Bianco, A. Fantinati, S. Salvadori, *R. Guerrini,* P. Secchiero, G. Zauli
J. Med. Chem. 59, 2016, 147-156

276) Beta-arrestin 2 rather than G protein efficacy determines the anxiolytic-versus antidepressant-like effects of nociceptin/orphanin FQ receptor ligands.
L. Asth, C. Ruzza, D. Malfacini, I. Medeiros, *R. Guerrini,* N. T. Zaveri, E. C. Gavioli, G. Calo'
Neuropharmacology. 105, 2016, 434-442

277) Nociceptin/orphanin FQ (N/OFQ) modulates immunopathology and airway hyperresponsiveness representing a novel target for the treatment of asthma.
S. R. Singh, N. Sullo, M. Matteis, G. Spaziano, J. McDonald, R. Saunders, L. Woodman, K. Urbanek, A. De Angelis, R. De Palma, R. Berair, M. Pancholi, V. Mistry, F. Rossi, *R. Guerrini*, G. Calò, B. D'Agostino, C. E. Brightling, D. G. Lambert
Br J Pharmacol. 173, 2016, 1286-1301

278) Intracellular quantitative detection of human thymidylate synthase engagement with an unconventional inhibitor using tetracysteine-diarsenical-probe technology
G. Ponterini, A. Martello, G. Pavesi, A. Lauriola, R. Luciani, M. Santucci, M. Pelà, G. Gozzi, S. Pacifico, *R. Guerrini*, G. Marverti, M. P. Costi, D. D'Arca
Sci Rep. 6, 2016, 27198

279) Characterisation of the Novel Mixed Mu-NOP Peptide Ligand Dermorphin-N/OFQ (DeNo).
M.F. Bird, M.C. Cerlesi, M. Brown, D. Malfacini, V. Vezzi, P. Molinari, L. Micheli, L. Di Cesare Mannelli, C. Ghelardini, R. Guerrini, G. Calò, D.G..Lambert
PLoS One 11, 2016, e0156897

280) Antidepressant activity of nociceptin/orphanin FQ receptor antagonists in the mouse learned helplessness.
V.A. Holanda, I.U. Medeiros, L. Asth, *R. Guerrini,* G. Calo', E. C.Gavioli
Psychopharmacology (Berl). 233, 2016, 2525-2532

281) Pharmacological characterization of cebranopadol a novel analgesic acting as mixed nociceptin/orphanin FQ and opioid receptor agonist

A. Rizzi, M. C. Cerlesi, C. Ruzza, D. Malfacini, F. Ferrari, S. Bianco, T. Costa, *R. Guerrini*, C. Trapella, G. Calo
Pharmacology Research & Perspectives. 4, 2016, e00247

282) AGHLDDLPGALSAL: A hemoglobin fragment potentially competing with albumin to bind transition metal ions.
G. Zamariola, J. Watly, E. Gallerani, R. Gavioli, *R. Guerrini*, H. Kozlowski, M. Remelli
J Inorg Biochem. 163, 2016, 301-310

283) DOES hemopressin bind metal ions in vivo?†
M. Remelli, C. Ceciliato, *R. Guerrini*, P. Kolkowska, K. Krzywoszynska, S. Salvadori, D.Valensin, J. Watlyb H. Kozlowski
Dalton Trans. 45, 2016, 18267-18280

284) In vitro functional characterization of novel nociceptin/orphanin FQ receptor agonists in recombinant and native preparations
F. Ferrari, M. C. Cerlesi, D. Malfacini, L. Asth, E. C. Gavioli, B. V. Journigan, U. G. Kamakolanu, M. E. Meyer, D. Yasuda, W. E. Polgar, A. Rizzi, *R. Guerrini*, C. Ruzza, N. T. Zaveri, G. Calo,
Eu. J. Pharmacol. 793 (2016) 1–13

285) Neuropeptide S receptor ligands: a patent review (2005-2016)
C. Ruzza, G. Calò, S. Di Maro, S. Pacifico, C. Trapella, S. Salvadori, D. Preti, *R. Guerrini*
Expert Opin Ther Pat. 27, 2017, 347-362

286) Pharmacological studies on the NOP and opioid receptor agonist PWT2-[Dmt^{1}]N/OFQ(1-13)
M. C. Cerlesi, H. Ding, M. F. Bird, N. Kiguchi, F. Ferrari, D. Malfacini, A. Rizzi, C. Ruzza, D. G. Lambert, M. C. Ko, G. Calo, *R. Guerrini*
Eu. J. Pharmacol. 794, 2017, 115-126

287) Involvement of cell surface TG2 in the aggregation of K562 cells triggered by gluten
G. Feriotto , R. Calza, C. Bergamini, M. Griffin, Z. Wang, S. Beninati, V. Ferretti , E. Marzola, *R. Guerrini,* A. Pagnoni, A. Cavazzini, F. Casciano, C. Mischiati
Amino Acids 49, 2017, 551-565.

288) Structure- and conformation-activity studies of nociceptin/orphanin FQ receptor dimeric ligands
S. Pacifico, A. Carotenuto, D. Brancaccio, E. Novellino, E. Marzola, F. Ferrari, M. C. Cerlesi, C. Trapella, D. Preti, S. Salvadori, G. Calò, R. Guerrini
Sci Rep. 2017, DOI: 10.1038/srep45817

289) Effects of [Nphe1, Arg14, Lys15] N/OFQ-NH2 (UFP-101), a potent NOP receptor antagonist, on molecular, cellular and behavioural alterations associated with chronic mild stress
G. Vitale, M. Filaferro, M. VM Di Bonaventura, V. Ruggieri, C. Cifani, *R. Guerrini,* M. Simonato, S. Zucchini
J. of Psychopharm. 6, 2017, 691-703

290) Synthesis and Biological Evaluation of Urotensin II(4-11) peptidomimetics Incorporating a 1,5-Triazole Disulfide Bond Mimic
S. Pacifico, A. Kerckhoffs, A. Fallows, *R. Guerrini,* J. McDonald, D. Lambert, A. Jamieson
Organic & Biomolecular Chemistry 15, 2017, 4704-4710

291) A diastereoselective synthesis of Cebranopadol, a novel analgesic showing NOP/mu mixed agonism
A. Fantinati, S. Bianco, *R. Guerrini*, S. Salvadori, S. Pacifico, M. C. Cerlesi, G. Calo', C. Trapella
Sci Rep. 2017, DOI:10.1038/s41598-017-02502-9

292) In vitro pharmacological characterization of a novel unbiased NOP receptor-selective nonpeptide agonist AT-403
F. Ferrari, D. Malfacini, B. Journigan, M. Bird, C. Trapella, *R. Guerrini*, D. Lambert, G. Calo
Pharmacology Research & Perspective 2017, 5, e00333

293) Fluorometric detection of protein-ligand engagement: The case ofphosphodiesterase5
G. Di Roccoa, I. Martinelli, S. Pacifico, *R. Guerrini*, E. Cichero, P. Fossa, S. Franchini, S. Cardarelli, M. Giorgi, M. Sola, G. Ponterini
Journal of Pharmaceutical and Biomedical Analysis 149, 2018, 335–342

294) Peptide welding technology – A simple strategy for generating innovative ligands for G protein coupled receptors.
G. Calo', A. Rizzi, C. Ruzza, F. Ferrari, S. Pacifico, E. C. Gavioli, S. Salvadori, *R. Guerrini*
Peptides 99, 2018, 195–204

295) Zn(II) and Ni(II) complexes with poly-histidyl peptides derived from a snake venom
M. Remelli, D. Brasili, *R. Guerrini*, F. Pontecchiani, S. Potocki, M. Rowinska-Zyrek, J. Watly, H. Kozlowski
Inorganica Chimica Acta 472, (2018), 149–156

296) In vitro and in vivo characterization of the bifunctional □ and □ opioid receptor ligand UFP-505
N. Dietis, H. Niwa, R. Tose, J. McDonald, V. Ruggieri, M. Filaferro, G. Vitale, L. Micheli, C. Ghelardini, S. Salvadori, G. Calo, *R. Guerrini*, D. J. Rowbotham D. G. Lambert
Br. J. Pharmacol. 175, 2018, 2881–2896

297) NOP receptor pharmacological profile-A dynamic mass redistribution study
D. Malfacini, K. Simon, C. Trapella, *R. Guerrini*, N. T. Zaveri, E. Kostenis, G. Calo
PLoS ONE 13, 2018, e0203021

298) Conformational Propensity and Biological Studies of Proline Mutated LR Peptides Inhibiting Human Thymidylate Synthase and Ovarian Cancer Cell Growth.
P. Saxena, L. Severi, M. Santucci, L. Taddia, S. Ferrari, R. Luciani, G. Marverti, C. Marraccini, D. Tondi, M. Mor, L. Scalvini, S. Vitiello, L. Losi, S. Fonda, S. Pacifico, *R. Guerrini*, D. D'Arca, G. Ponterini, Maria Paola Costi
J. Med. Chem. 61, 2018, 7374-7380

299) Glycation affects fibril formation of A□ peptides
A. Emendato, G. Milordini, E. Zacco, A. Sicorello, F. Dal Piaz, *R. Guerrini*, R. Thorogate, D. Picone, A. Pastore
J. Biol. Chem. 293, 2018, 13100-13111

300) Design and synthesis of a new class of 99mTcN -labeled destran-mannose derivatives for sentinel lymph node detection.
A. Boschi, M. Pasquali, C. Trapella, A. Massi, P. Martini, A. Duatti, R. Guerrini, V. Zanirato, A. Fantinati, E. Marzola, M. Giganti, L. Uccelli
Pharmaceuticals 2018, 11, 70; doi:10.3390/ph11030070

301) Pharmacological profile of the neuropeptide S receptor: Dynamic mass redistribution studies
C. Ruzza, F. Ferrari, R. Guerrini, E. Marzola, D. Preti, R. K. Reinscheid, G. Calo
Pharmacol Res Perspect. 2018;e00445.

302) NOP agonists prevent the antidepressant-like effects of nortriptyline and fluoxetine but not r-ketamine.
V. A. Duarte Holanda, W. B. Santos, L. Asth, *R. Guerrini*, G. Calo', C. Ruzza, E. C. Gavioli
Psychopharmacology 2018, 235, 3093-3102

303) Nociceptin/Orphanin FQ (N/OFQ) conjugated to ATTO594: a novel fluorescent probe for the N/OFQ (NOP) receptor.
Bird MF, *Guerrini R*, Willets JM, Thompson JP, Caló G, Lambert DG.
Br. J. Pharmacol. 2018, 175, 4496-4506

304) Disordered Peptides Looking for Their Native Environment: Structural Basis of CB1 Endocannabinoid Receptor Binding to Pepcans.
Emendato A, *Guerrini R*, Marzola E, Wienk H, Boelens R, Leone S, Picone D.
Front. Mol. Biosci. 2018, 5, Article 100

305) Probing the effect of sildenafil on Progesterone and Testosterone production by an intracellullar FRET/BRET combined approach"
Authors: L. Casarini , L. Riccetti, S. Limoncella, C. Lazzaretti, F. Barbagallo, S. Pacifico, R. Guerrini, S. Tagliavini, T. Trenti , M. Simoni , M. Sola, G. Di Rocco.
Biochemistry, 2019, 58, 799–808

306) Nociceptin/Orphanin fq receptor agonists increase aggressiveness in the mouse resident intruder test.
E. F. Silva, A. I. Silva, L. Asth, L. S. Souza, N. T. Zaveri, *R. Guerrini*, G. Calo', C. Ruzza, E. C. Gavioli
Behavioural Brain Research 2019, 356, 120–126.